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Abstract 
ANTI STREPTOKINASE ANTIBODIES AND RESPONSE TO THROMBOLYSIS  
WITH STREPTOKINASE   IN ST SEGMENT ELEVATION MYOCARDIAL 
INFARCTION 
 
Background :  In India 60% of the patients with Acute Coronary Syndromes 
(ACS) present with ST segment elevation myocardial infarction (STEMI). Majority 
of these patients undergo thrombolysis with streptokinase (STK) for reperfusion. 
Studies have however shown that anti streptokinase (ASTK) antibodies in the 
serum neutralise the effect of STK. It has also been shown that the ASTK 
antibody titres are significantly elevated in the Indian population. We sought to 
assess the effect of ASTK antibodies on the efficacy of STK when used for 
reperfusion in patients with STEMI. 
METHODS: Patients presenting to us with STEMI and planned to receive STK 
for reperfusion were enrolled in the study. Before initiation of thrombolysis, 3-4 ml 
of blood sample was collected for estimation of ASTK antibody titres. The 
patients were divided into two groups, those with window period less than and 
more than 6 hours. The baseline data was collected and the clinical markers of 
reperfusion were recorded. All the patients were subsequently followed up for 30 
days and any major adverse cardiac events (MACE), if present, were noted. 
RESULTS: We enrolled a total of 148 patients of which 133 patients (90%) were 
males. The mean window period (WP) at presentation was 5hrs 45min. Patients 
presenting directly to our centre numbered 46 while 102 patients were referred 
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from elsewhere. The mean WP in patients presenting directly to our centre was 
2hrs 48 min while in the other patients it was 7hrs 5min.There was significant 
effect of time on reperfusion in both patients having low (P<0.001) and high 
(P=0.006) titres. There was also a significant effect of presence of ASTK 
antibodies. Patients who responded to thrombolysis were more likely to have low 
titres while those who did not respond had high ASTK antibody titres. This 
pattern was seen in both patients presenting before a WP of 6 hrs (P<0.001) and 
those presenting after 6 hrs (P=0.007). 
MACE was noted in 30 (21%) patients. Patients with MACE were more likely to 
have high baseline ASTK antibody titres than those without MACE (P=0.042). 
The effect of ASTK antibodies appeared to have been present in both patients 
presenting before 6hrs (P=0.067) and after 6hrs (P=0.27). 
CONCLUSION: ASTK antibodies are widely prevalent in the general population 
in varying titres. They seem to significantly impair the thrombolytic effect of STK 
in patients with STEMI. Patients with low ASTK antibody titre are more likely to 
benefit from thrombolysis with STK. Also those who develop MACE within 30 
days of the event are more likely to have high ASTK antibody titre. Thus the 
presence of high ASTK antibody titres act as a poor prognostic marker in patients 
with STEMI undergoing thrombolysis with STK. 
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INTRODUCTION 
 
Ischemic heart disease is the most common cause of death in both the 
developing and the developed countries1.  By 2020 these diseases are expected 
to increase by more than 120% in the developing countries, compared to 30-60% 
in the developed countries2. 60% of the world’s heart disease is expected to 
occur in India3. This brings a huge challenge to the healthcare system which is 
already inadequate and over stretched. Providing them the optimal care in the 
Indian settings will need more concrete data applicable to the general population. 
More studies need to be conducted in the local population as the findings of 
studies conducted in the western population may not be directly applicable to the 
Indian population. 
 
Ischemic heart disease (IHD) continues to be the leading cause of death in the 
developed countries, but the spectrum appears to be different from that of the 
Indian population. Fewer than 40% of the patients with acute coronary 
syndromes (ACS) present with ST segment elevation myocardial infarction 
(STEMI) in the developed countries4,5. This is also showing a decreasing trend 
with time. On the other hand 60% of patients with ACS present with STEMI in 
India6. This suggests that patients with ACS are likely to have a worse prognosis 
in India than in the western countries. Appropriate management of STEMI is very 
important to decrease mortality as well as long term morbidity. 
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The most important management in the patients with STEMI, other than the 
usual drugs, is an early reperfusion therapy7. The different modes available for 
reperfusion presently is by either a fibrinolytic agent or primary percutaneous 
transluminal coronary angioplasty (PTCA). Fibrinolysis when introduced was a 
major breakthrough in coronary care and showed an 18% relative risk reduction 
in mortality at 30 days8. Subsequent introduction of primary PTCA showed further 
reduction in mortality compared to thrombolysis9. This has established primary 
PTCA as the treatment of choice for STEMI provided it is done in the set time 
limit as described7. However primary PTCA needs a larger set up and expertise 
which is still not widely available. In India only around 8% of the patients undergo 
PTCA while more than 50% of the patients undergo thrombolysis6. There are 
many thrombolytic agents available now with the fibrin selective agents showing 
better results than the non selective agent streptokinase10. However because of 
the high costs associated with the fibrin specific agents, streptokinase continues 
to be the most commonly used thrombolytic agent in the developing countries. 
 
Streptokinase (STK) is an extracellular non-enzymatic protein produced by 
various strains of beta haemolytic streptococci.  However, a disadvantage to its 
use is its antigenicity due to the widespread presence of antibodies in the 
population, presumed secondary to previous streptococcal exposure or infection. 
A measurable level of antibodies to STK is nearly omnipresent in the population 
as a consequence of the high frequency of streptococcal infection11. Presence of 
high levels of anti streptokinase (ASTK) antibodies are likely to inhibit the 
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fibrinolytic activity. Clinical failure of the activation of the fibrinolytic system by 
STK has been reported due to the presence of a high titre of ASTK antibodies12. 
This could be especially problematic in populations with high endemic 
streptococcal infections where the ASTK antibody titres are much higher than 
those in the western countries13. The antibody titres are similarly very high in the 
Indian population too14. Under these circumstances the benefit of STK can not be 
guaranteed in the general population. 
 
Studies have been done to evaluate the effect of ASTK antibodies on the 
outcome of thrombolysis. These studies have shown a varying picture with some 
reporting no effect on the outcome of thrombolysis15,16 and some suggesting a 
failure of thrombolysis due to high antibody titres17,18,19. However, most of these 
studies were carried out without having taken the window period into account and 
only the markers of reperfusion were assessed. 
 
Most of the patients in India receive thrombolytic therapy as the mode of 
reperfusion. This is mainly because the patients have to pay themselves for their 
treatment and can not afford the costlier option of primary percutaneous 
transluminal coronary angioplasty (PTCA)6. While this being one factor, another 
factor could also be that most of the patients are seen initially at a centre without 
facilities for primary PTCA and thrombolysed with STK to avoid a delay in shifting 
to a higher centre. However, in view of the possibility of failure of STK as the 
thrombolytic agent, it may be prudent to tailor the therapy in individual cases. 
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This needs careful consideration given the fact that the benefit of primary PTCA 
continues to be similar even upto 12 hours of presentation. This optimization 
could be in the form of emphasizing the need to use the newer fibrin specific 
agents which are not affected by the presence of the ASTK antibodies or 
allowing a longer door to balloon period for primary PTCA especially in those 
patients who have longer window periods at presentation and are also likely to 
have high ASTK antibody titres. 
 
This study was planned to assess the outcome of thrombolysis in patients 
thrombolysed with STK and effect of presence of ASTK antibodies in the serum. 
It was planned to assess the immediate reperfusion based on clinical criteria and 
also to look for clinical end points of rest angina, reinfarction, heart failure and 
death at 30 days and to see if it is affected in anyway by the presence of ASTK 
antibodies. 
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AIMS AND OBJECTIVES 
 
1. To assess the clinical criteria for reperfusion in patients with STEMI who 
were thrombolysed with streptokinase. 
 
2. To follow up these patients for 30 days and look for any major adverse 
cardiac event namely rest angina, reinfarction, heart failure or death. 
 
3. To estimate the anti streptokinase antibody titres in these patients in a 
serum sample collected prior to them receiving streptokinase 
 
4. To assess any correlation between the antibody titres and successful 
thrombolysis or the major adverse cardiovascular events. 
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REVIEW OF LITERATURE 
 
Epidemiology 
Cardiovascular disease (CVD) is a major cause of disability and premature death 
throughout the world, and contributes substantially to the escalating costs of 
health care. The underlying pathology is atherosclerosis, which develops over 
many years and is usually advanced by the time symptoms occur, generally in 
middle age. Acute coronary and cerebrovascular events frequently occur 
suddenly, and are often fatal before medical care can be given. 
 
Of an estimated 58 million deaths globally from all causes in 2005, 
cardiovascular disease accounted for 30%. This proportion is equal to that due to 
infectious diseases, nutritional deficiencies, and maternal and perinatal 
conditions combined20. It is important to recognize that a substantial proportion of 
these deaths (46%) were of people under 70 years of age, in the more productive 
period of life21. 
 
CVDs are no longer confined by geographical area or by age, sex, or 
socioeconomic boundaries. Heart disease has already reached epidemic 
proportions in poorer countries. Except in Africa, noncommunicable diseases 
outnumbered communicable diseases in all WHO regions worldwide. In 
Southeast Asia alone, 7 423 000 deaths were due to noncommunicable diseases  
as  compared with 5 730 000 deaths related to communicable diseases in the 
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year 2002. Globally, ischemic heart disease (IHD) was the leading killer in the 
age group ≥60 years, and, with 1332000 deaths in adults aged 15–59 years, IHD 
was ranked behind HIV/AIDS only22. 
 
It is to be noted however that the principal cardiovascular disorder responsible for 
the global rise in mortality is no longer rheumatic heart disease, but rather 
atherosclerotic vascular disease. Ischemic heart disease  is the leading cause of 
death in the world, and cerebrovascular disease is the second leading cause23,24. 
Cardiovascular diseases are responsible for 30% of all deaths worldwide each 
year23,24. It is often assumed that atherosclerosis is a disease of affluent, 
industrialized countries. However, 80% of these deaths occur in low-to-middle 
income countries of varying size like China, Russia, Poland, Mauritius, Argentina, 
and India23. 
 
Cardiovascular disease in India 
India is in the midst of a demographic transition. The average life expectancy at 
birth in India is 63.7 years, being 63.1 for males and 64.4 for females, compared 
with the national average of 41.2 years in 1951–196122. There has been a 
decline in death rate from 1941 to 1971, followed by a sharp decline in birth rate 
from 1971 onwards. This rise in life expectancy in India is attributed to a 
decrease in infectious, parasitic, and nutritional disorders and, in itself, is a 
remarkable achievement. However, this demographic transition has also led to 
an increase in the number of older people (aged ≥60 years), from 19.61 million in 
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1950 to 75.93 million in 2000. The increase in life expectancy has brought a large 
section of the population to an age where CVD starts manifesting itself. In India, 
coronary artery disease (CAD) rates have increased during the last 30 years, 
whereas declining trends have been noticed in the developed Western 
countries22. 
 
Reports on CAD in Indians from different parts of the world have shown that 
Indians are at 3–4 times higher risk of CAD than white Americans, 6 times higher 
than Chinese, and 20 times higher than Japanese25,26,27. The exact prevalence of 
CAD in India is difficult to estimate owing to the lack of a large prospective study. 
Absence of a centralized death registry for CVDs and irregularities in completion 
of death certificates also hamper estimation of the actual burden of CVD. 
 
Heart diseases are occurring in Indians 5 to 10 years earlier than in other 
populations around the world28,29. According to the INTERHEART study, the 
median age for first presentation of acute MI in the South Asian (Bangladesh, 
India, Nepal, Pakistan, Sri Lanka) population is 53 years, whereas that in 
Western Europe, China, and Hong Kong is 63 years, with more men than women 
affected30. 
 
The first myocardial infarction (MI) occurs in 4.4% of Asian women and 9.7% of 
men at age less than 40 years, which is 2 to 3.5 fold higher than in the West 
European population and is third highest of all the regions studied worldwide30. 
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The INTERHEART study30, involving 52 countries, established an association 
between conventional modifiable risk factors for MI in all regions of the world, 
including South Asia, and in both sexes and at all ages. In South Asians, 
apolipoprotein (Apo) B/ApoA1  and smoking were the important risk factors, as in 
the rest of the world. However, hypertension, abdominal obesity, and diabetes 
had more severe effects in South Asia. The study also showed that hypertension 
and diabetes were more important risk factors in younger Indian women than 
men. It was also observed that the risk of CAD increased incrementally with 
smoking and it was a greater risk factor in younger men than in women.  
 
It has also been shown that the majority of MI risk in native South Asians can be 
explained by 9 potentially modifiable risk factors with similar collective impact as 
in other countries31. These are – 
• Apolipoprotein B100/apolipoprotein A-I ratio 
• Current and former smoking 
• Hypertension 
• Diabetes 
• High waist-to-hip ratio 
• Psychosocial factors (stress or depression) 
• Moderate- or high-intensity exercise 
• Alcohol consumption 
• Consumption of fruits and vegetables 
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South Asians had a lower age at presentation of first MI. The younger age of first 
MI among the South Asian cases is largely because of the higher prevalence of 
risk factors in native South Asians. 
 
The 4 main risk factors, which showed consistently significant associations 
across all South Asian countries in both sexes were current and former smoking, 
high ApoB100/Apo-I ratio, history of hypertension, and history of diabetes. 
 
The 9 risk factors collectively explained 86.0% of the risk in South Asians and 
suggested that modifying behavior related to known risk factors could lead to a 
substantial impact31.  
 
Between 1990 and 2020, ischemic heart diseases are expected to increase by 
120% for women and 137% for men in developing countries, compared with 30-
60% in developed countries2. By 2010, 60% of the world's heart disease is 
expected to occur in India3. In addition, the proportion of patients with STEMI at 
60% of the acute coronary syndrome patients is much higher than the proportion 
observed in developed countries where fewer than 40% had STEMI5. This 
suggests that the patients with acute coronary syndromes in India are likely to 
have a worse prognosis than the patients in western countries. Also the average 
age of ACS in India at 57 years is also much lower than that in western countries. 
They also take longer time to reach hospitals, and longer time to initiation of 
treatment. The majority of patients receive thrombolytic therapy as the means for 
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reperfusion with only 8% of STEMI patients being treated with primary PTCA. 
Correspondingly the 30 days mortality rate in Indian patients with ACS is higher 
than in registries in high income countries6. 
 
Myocardial Infarction 
Myocardial infarction is defined by pathology as myocardial cell death due to 
prolonged ischemia. Cell death is categorized pathologically as coagulation 
and/or contraction band necrosis, which usually evolves through oncosis, but can 
result to a lesser degree from apoptosis32. 
 
After the onset of myocardial ischemia, cell death is not immediate but takes a 
finite period to develop (as little as 20 min or less in some animal models). It 
takes several hours before myocardial necrosis can be identified by macroscopic 
or microscopic post-mortem examination. Complete necrosis of all myocardial 
cells at risk requires at least 2–4 h or longer depending on the presence of 
collateral circulation to the ischemic zone, persistent or intermittent coronary 
arterial occlusion, the sensitivity of the myocytes to ischemia, preconditioning, 
and/or, finally, individual demand for myocardial oxygen and nutrients.  
 
Myocardial infarction is generally the result of acute rupture or ulceration of an 
atherosclerotic plaque situated within a major epicardial coronary artery. 
Exposure of the intimal layer initiates a cascade of platelet activation and 
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thrombosis resulting in occlusion of the vessel and infarction of the subjacent 
myocardium32. 
 
Myocardial infarctions are usually classified by size: microscopic (focal necrosis), 
small (<10% of the LV myocardium), moderate (10–30% of the LV myocardium), 
and large (>30% of the LV myocardium), and by location32. 
 
Definition of myocardial infarction 
Myocardial infarction can be defined pathologically as acute, healing, or healed. 
Acute myocardial infarction is characterized by the presence of 
polymorphonuclear leukocytes. If the time interval between the onset of the 
infarction and death is quite brief, e.g. 6 h, minimal or no polymorphonuclear 
leukocytes may be seen. The presence of mononuclear cells and fibroblasts, and 
the absence of polymorphonuclear leukocytes characterize healing infarction. 
Healed infarction is manifested as scar tissue without cellular infiltration. The 
entire process leading to a healed infarction usually takes at least 5–6 weeks. 
Reperfusion may alter the macroscopic and microscopic appearance of the 
necrotic zone by producing myocytes with contraction bands and large quantities 
of extravasated erythrocytes. Myocardial infarctions can be classified temporally 
from clinical and other features, as well as according to the pathological 
appearance, as evolving (<6 h), acute (6 h–7 days), healing (7–28 days), and 
healed (29 days and beyond)32.  
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Criteria for acute myocardial infarction 
The term myocardial infarction should be used when there is evidence of myocardial necrosis in a 
clinical setting consistent with myocardial ischaemia. Under these conditions any one of the following 
criteria meets the diagnosis for myocardial infarction: 
• Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value 
above the 99th percentile of the upper reference limit (URL) together with evidence of 
myocardial ischaemia with at least one of the following 
 Symptoms of ischaemia; 
 ECG changes indicative of new ischaemia [new ST-T changes or new left bundle 
branch block (LBBB)]; 
 Development of pathological Q waves in the ECG; 
 Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality. 
• Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive 
of myocardial ischaemia, and accompanied by presumably new ST elevation, or new LBBB, 
and/or evidence of fresh thrombus by coronary angiography and/or at autopsy, but death 
occurring before blood samples could be obtained, or at a time before the appearance of 
cardiac biomarkers in the blood. 
• For percutaneous coronary interventions (PCI) in patients with normal baseline troponin 
values, elevations of cardiac biomarkers above the 99th percentile URL are indicative of peri-
procedural myocardial necrosis. By convention, increases of biomarkers greater than 3x99th 
percentile URL have been designated as defining PCI-related myocardial infarction. A 
subtype related to a documented stent thrombosis is recognized. 
• For coronary artery bypass grafting (CABG) in patients with normal baseline troponin values, 
elevations of cardiac biomarkers above the 99th percentile URL are indicative of peri-
procedural myocardial necrosis. By convention, increases of biomakers greater than 5x99th 
percentile URL plus either new pathological Q waves or new LBBB, or angiographically 
documented new graft or native coronary artery occlusion, or imaging evidence of new loss 
of viable myocardium have been designated as defining CABG-related myocardial infarction. 
• Pathological findings of an acute myocardial infarction. 
 
Criteria for prior myocardial infarction 
Any one of the following criteria meets the diagnosis for prior myocardial infarction: 
• Development of new pathological Q waves with or without symptoms. 
• Imaging evidence of a region of loss of viable myocardium that is thinned and fails to 
contract, in the absence of a non-ischaemic cause. 
• Pathological findings of a healed or healing myocardial infarction. 
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ECG abnormalities of myocardial ischemia or infarction may be inscribed in the 
PR segment, the QRS complex, and the ST segment or T-waves. The earliest 
manifestations of myocardial ischemia are typical T-waves and ST segment 
changes33. Increased hyper-acute T-wave amplitude with prominent symmetrical 
T-waves in at least two contiguous leads is an early sign that may precede the 
elevation of the ST segment. Increased R-wave amplitude and width (giant R-
wave with S-wave diminution) are often seen in leads exhibiting ST elevation, 
and tall T-waves reflecting conduction delay in the ischemic myocardium34. 
Transient Q-waves may be observed during an episode of acute ischemia or 
rarely during acute myocardial infarction with successful reperfusion35. 
 
The J-point is used to determine the magnitude of the ST elevation. J-point 
elevation in men decreases with increasing age; however, that is not observed in 
women, in whom J-point elevation is less than in men36. 
 
Contiguous leads means lead groups such as anterior leads (V1-V6), inferior 
leads (II, III, and aVF), or lateral/apical leads (I and aVL).  Supplemental leads 
such as V3R and V4R reflect the free wall of the right ventricle. 
 
Although the criteria require that the ST shift be present in two or more 
contiguous leads, occasionally acute myocardial ischemia may create sufficient 
ST segment shift to meet the criteria in one lead but have slightly less than the 
required ST shift in an adjacent contiguous lead. Lesser degrees of ST 
24 
 
displacement or T-wave inversion in leads without prominent R-wave amplitude 
do not exclude acute myocardial ischemia or evolving myocardial infarction. 
 
Reperfusion strategy in myocardial infarction 
Although rapid spontaneous reperfusion of the infarct artery may occur, in the 
majority of patients there is persistent occlusion of the infarct artery in the first 6 
to 12 hours while the affected myocardial zone is undergoing necrosis. Prompt 
and complete restoration of flow in the infarct artery can be achieved by 
pharmacological means (fibrinolysis), percutaneous coronary intervention (PCI) 
[balloon angioplasty with or without deployment of an intracoronary stent under 
the support of pharmacological measures to prevent thrombosis], or surgical 
measures. Evidence exists that expeditious restoration of flow in the obstructed 
infarct artery after the onset of symptoms in patients with STEMI is a key 
determinant of short- and long-term outcomes regardless of whether reperfusion 
is accomplished by fibrinolysis or PCI37,38,39. 
 
A critically important goal of reperfusion is to restore flow in the infarct artery as 
quickly and as completely as possible, but the ultimate goal of reperfusion in 
STEMI is to improve myocardial perfusion in the infarct zone. Despite adequate 
restoration of flow in the epicardial infarct artery, perfusion of the infarct zone 
may still be compromised by a combination of microvascular damage and 
reperfusion injury40,41. Microvascular damage occurs as a consequence of 
downstream embolization of platelet microemboli and thrombi followed by the 
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release of substances from activated platelets that promote occlusion or spasm 
in the microvasculature. Reperfusion injury results in cellular edema, free radical 
formation, calcium overload, and acceleration of the apoptotic process. Cytokine 
activation in the infarct zone leads to neutrophil accumulation and inflammatory 
mediators that contribute to tissue injury. 
 
Time from onset of symptoms to fibrinolytic therapy is an important predictor of 
MI size and patient outcome42. The efficacy of fibrinolytic agents in lysing 
thrombus diminishes with the passage of time43. Fibrinolytic therapy administered 
within the first 2 hours (especially the first hour) can occasionally abort MI and 
dramatically reduces mortality8,44. Because the benefit of fibrinolytic therapy is 
directly related to the time from symptom onset, treatment benefit is maximized 
by the earliest possible application of therapy.  
 
The present recommendations for fibrinolytic therapy say that: 
In the absence of contraindications, fibrinolytic therapy should be administered to 
STEMI patients with symptom onset within the prior 12 hours and ST elevation 
greater than 0.1 mV in at least 2 contiguous precordial leads or at least 2 
adjacent limb leads or patients with symptom onset within the prior 12 hours and 
new or presumably new LBBB. 
 
In the absence of contraindications, it is reasonable to administer fibrinolytic 
therapy to STEMI patients with symptom onset within the prior 12 hours and 12-
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lead ECG findings consistent with a true posterior MI. It is also reasonable to 
administer fibrinolytic therapy to patients with symptoms of STEMI beginning 
within the prior 12 to 24 hours who have continuing ischemic symptoms and ST 
elevation greater than 0.1 mV in at least 2 contiguous precordial leads or at least 
2 adjacent limb leads7. 
 
Contraindications and Cautions for Fibrinolysis Use in ST-Elevation 
Myocardial Infarction7 
Absolute contraindications 
• Any prior ICH 
• Known structural cerebral vascular lesion (eg, AVM) 
• Known malignant intracranial neoplasm (primary or metastatic) 
• Ischemic stroke within 3 months EXCEPT acute ischemic stroke within 3 
hours 
• Suspected aortic dissection 
• Active bleeding or bleeding diathesis (excluding menses) 
• Significant closed head or facial trauma within 3 months 
Relative contraindications 
• History of chronic severe, poorly controlled hypertension 
• Severe uncontrolled hypertension on presentation (SBP greater than 180 mm 
Hg or DBP greater than 110 mm Hg)† 
• History of prior ischemic stroke greater than 3 months, dementia, or known 
intracranial pathology not covered in contraindications 
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• Traumatic or prolonged (greater than 10 minutes) CPR or major surgery (less 
than 3 weeks) 
• Recent (within 2 to 4 weeks) internal bleeding 
• Noncompressible vascular punctures 
• For streptokinase/anistreplase: prior exposure (more than 5 days ago) or prior 
allergic reaction to these agents 
• Pregnancy 
• Active peptic ulcer 
• Current use of anticoagulants: the higher the INR, the higher the risk of 
bleeding 
 
The constellation of clinical features that must be present to serve as an 
indication for fibrinolysis includes symptoms of myocardial ischemia and ST 
elevation fulfilling the criteria as mentioned, or new or presumably new LBBB on 
the presenting ECG8,45. In the very early phase of STEMI, giant hyperacute T 
waves may precede ST elevation46. True posterior MI may be manifested by tall 
R waves in the right precordial leads and ST-segment depression in leads V1 
through V4, especially when T waves are upright. Repeat ECGs and 
incorporation of additional leads such as V7 through V9 are more specific for the 
detection of posterior infarction. Patients with LBBB or anterior ST elevation are 
at greater inherent risk from MI and achieve greater benefit with fibrinolytic 
therapy. 
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Efficacy of intravenous fibrinolytic therapy in STEMI 
It has been well established that fibrinolytic therapy provides a survival benefit for 
patients with STEMI, based on large, well-controlled clinical trials47,48,49. The 
mechanisms of benefit, which may have different time dependencies, include 
salvage of myocardium with reduced infarct size, favourable effect on infarct 
healing and myocardial remodeling, and reduced electrical heterogeneity and 
potential for life-threatening ventricular arrhythmia50.  
 
An overview of  the  results of 9  trials by  the Fibrinolytic  Therapy Trialists’ 
Collaborative Group comparing the outcomes of patients undergoing fibrinolytic 
therapy and those of  controls  demonstrated  a highly significant 18% relative 
reduction in 35-day mortality (9.6% fibrinolysis versus 11.5% control), which 
corresponds to absolute reductions  in 35-day mortality  rates of approximately 
30 per 1000 for patients who arrived at the hospital within 6  hours of the onset of 
symptoms and of approximately 20 per 1000 for patients who arrived 7 to 12 
hours after the onset  of symptoms8. This survival benefit is maintained over the 
long term (up to 10 years). Mortality reduction from fibrinolytic therapy is greatest 
within the first hour after symptom onset; thereafter, decline in benefit of 
approximately 1.6 lives per 1000 patients treated is seen per 1-hour delay. 
 
Thrombolytic agents 
The fibrinolytic agents currently approved for treating patients with STEMI include  
streptokinase,  alteplase,  reteplase, and tenecteplase . These agents are 
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commonly referred to as plasminogen activators, since their mode of action is 
through the conversion of the enzymatically inert plasminogen (PG) of the 
fibrinolytic system to an active protease, plasmin (PN), that dissolves the fibrin 
clots and solubilises degradation products, which can be removed by the 
phagocytes. 
 
STREPTOKINASE 
Streptokinase was the first available and most widely studied agent for 
thrombolysis. Streptokinase (STK) is an extracellular non-enzymatic protein 
produced by various strains of beta haemolytic streptococci. STK is a single-
chain protein of molecular weight 47 kDa containing 414 amino acids, having 
isoelectric pH 4.751. The enzyme has its maximum activity between pH 7.3 and 
7.6. The capacity of STK to cause lysis of blood clots was first described by Tillet 
and Carner in 1933 and the effect was thought to be a direct enzymatic action on 
fibrin. Milstone in 1941 demonstrated that STK achieved its effect through 
activation of plasma protein. At first STK was called fibrinolysin, until it was found 
that it induced fibrinolysis indirectly through activation of a plasma protein in the 
fibrinolysis system in man. The term streptokinase was then coined by 
Christensen to describe the bacterial extract52. 
 
STK has no proteolytic activity of its own and thus activates PG to PN indirectly 
by first forming a high affinity equimolar complex with PG (STK–PG activator 
complex)51. It forms a 1:1 complex with plasminogen causing conversion to 
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plasmin. It is nonspecific, activating circulating as well as clot-bound 
plasminogen, and causes extensive fibrinogen depletion.  
 
Streptokinase is antigenic. Neutralizing antibodies are significant following use, 
and repeat administration should be avoided. Allergic reaction (rash, chills, 
urticaria) occurs in around 4% of patients and anaphylactic shock occurs in 0.5% 
of patients48. Hypotension can be significant (average decrease ~ 35 mm systolic 
blood pressure (SBP)53 and may be worsened by rapid administration, which 
excludes bolus use and necessitates constant IV infusion. It is commonly given 
as 1.5 million units over 60 min.  
 
ALTEPLASE 
Tissue type plasminogen activator (t-PA) is a naturally occurring serine protease, 
which is produced by healthy endothelium. Its levels are increased with exercise 
and inhibited by plasminogen activator inhibitor (PAI-1). Alteplase is a 
commercially available, genetically engineered, bacterially produced version of 
human t-PA.  It exhibits marked specificity for the plasminogen-fibrin complex, 
although at the doses necessary to achieve rapid lysis, there is ~ 50% depletion 
of circulating fibrinogen. t-PA is associated with a higher early recanalization rate 
relative to streptokinase54, but may be accompanied by an increase rate of 
reocclusion55. The half-life is approximately 5 min; thus, t-PA must be 
administered via continuous IV infusion over 90 min. 
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The accelerated dosing regimen has been proven to be the most effective56: 15 
mg bolus over 1–2 min followed by 0.75 mg/kg IV (≤ 50mg) over 30 min followed 
by 0.5 mg/kg (≤ 35 mg) over 60 min. 
 
Weight adjustment is recommended because of excessive bleeding in lighter 
weight (<60 kg) patients and a trend toward decreased lysis in heavy weight (>90 
kg) individuals57. Higher dose and double-bolus regimens have been associated 
with unacceptable bleeding rates58,59. The accelerated or front-loaded dosing 
regimen has been shown to have higher early patency rates, similar safety 
profile56, and lower incidences of reocclusion as compared with the standard 
dosing regimen60. 
 
The TIMI (Thrombolysis  in Myocardial  Infarction),  phase  1  trial  randomly  
assigned 290 patients with evolving acute MI to alteplase or  to  streptokinase.  
Alteplase was far superior in achieving coronary reperfusion; twice as many 
occluded infarct-related arteries opened after 90 minutes with alteplase than with 
streptokinase61. 
 
The GUSTO I study (41,021 patients) tested the accelerated dose regimen 
combined with intravenous heparin. Despite an increase in intracerebral bleeding 
with t-PA, overall benefit as assessed from the combined endpoint of total 
mortality and disabling stroke was significantly better with t-PA as compared with 
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streptokinase (6.3% vs. 7.3%)10. This translates into a 15% mortality reduction or 
about 10 lives saved per 1,000 patients treated. 
 
RETEPLASE 
Reteplase is a deletion mutant of t-PA that exhibits preferential activation of 
fibrin-bound plasmin and a two to threefold increase in half-life (15 min), 
permitting bolus administration. It has a lower affinity to fibrin (theoretically 
improving clot penetration), though similar fibrin specificity compared with 
alteplase. While initial studies showed superior infarct artery patency when 
compared with conventional dose t-PA in the RAPID I trial62 and accelerated 
dose t-PA in the RAPID-2 trial63, the GUSTO III study (15,059 patients) showed 
equivalent 30-day mortality rates with reteplase (7.5%) versus accelerated-dose 
alteplase (7.2%). The rates of the combined endpoint, death, or nonfatal MI-
disabling stroke were similar: 7.98% and 7.91%, respectively64. 
 
Reteplase offers the advantage of double-bolus administration: 10 units IV 
followed by another 10 units 30 min later. Additionally, no weight adjustment is 
required. 
 
TENECTEPLASE 
Tenecteplase (TNK-t-PA) is the triple mutant form of t-PA that is highly fibrin-
specific, exhibits decreased plasma clearance, and is resistant to plasminogen 
activator inhibitor (PAI-1) secreted by activated platelets. Its prolonged half-life 
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(~20 min) permits it to be dosed as a weight-adjusted 30–50 mg single bolus 
given over 2–5sec. The recommended dose is 30 mg for persons less than 60 
kg, 35 mg for 60–70 kg, 40 mg for 70–80 kg, 45mg for 80–90 kg, and 50 mg > 90 
kg.  
 
Efficacy was demonstrated in the ASSENT II study (16,949 patients) that 
compared tenecteplase to accelerated dose t-PA. The incidence of death or 
nonfatal stroke was 7.11% for TNK-t-PA and 7.04% for t-PA. Intracranial 
hemorrhage occurred in 0.93% and 0.94%, respectively. There was a 
significantly lower incidence of major noncerebral bleeding, 4.66% and 5.94%, as 
well as all noncerebral bleeding, 26.4% vs. 29%, resulting in a lower need for 
blood transfusion in the TNK-t-PA group. The incidence of CABG (5.5% vs. 
6.2%) and development of heart failure (6.1 vs. 7.0) were significantly lower in 
the TNK-t-PA group65. The 30-day mortality rates were virtually identical; this 
outcome met the predefined criteria for  equivalence. As a single-bolus agent, 
tenecteplase has become the most widely used fibrin-specific agent. 
 
Evidence exists that expeditious restoration of flow in the obstructed infarct artery 
after the onset of symptoms in STEMI patients is a key determinant of short- and 
long-term outcomes regardless of whether reperfusion is accomplished by 
fibrinolysis or PCI37-39. 
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Efforts should be made to shorten the time for rapid recognition and treatment of 
patients with STEMI such that door-to-needle (or medical contact–to-needle) time 
for initiation of fibrinolytic therapy can be achieved within 30 minutes or that door-
to-balloon (or medical contact–to-balloon) time for PCI can be kept under 90 
minutes. 
 
SELECTION OF REPERFUSION STRATEGY 
Several issues should be considered in selecting the type of reperfusion therapy:  
Time From Onset of Symptoms: Time from onset of symptoms to fibrinolytic 
therapy is an important predictor of MI size and patient outcome42. The efficacy 
of fibrinolytic agents in lysing thrombus diminishes with the passage of time43. 
Fibrinolytic therapy administered within the first 2 hours (especially the first hour) 
can occasionally abort MI and dramatically reduce mortality8,44. 
 
Choice of reperfusion therapy is also affected by the patient’s risk of bleeding. 
When both types of reperfusion are available, the higher the patient’s risk of 
bleeding with fibrinolytic therapy, the more strongly the decision favours PCI. If 
PCI is unavailable, then the benefit of pharmacological reperfusion therapy is 
balanced against the risk. 
 
STEMI patients presenting to a facility without the capability for expert, prompt 
intervention with primary PCI within 90 minutes of first medical contact undergo 
fibrinolysis unless contraindicated. 
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Primary percutaneous transluminal coronary angioplasty 
If immediately available, primary PCI should be performed in patients with STEMI 
(including true posterior MI) or MI with new or presumably new LBBB who can 
undergo PCI of the infarct artery within 12 hours of symptom onset, if performed 
in a timely fashion (balloon inflation within 90 minutes of presentation).  
 
Primary percutaneous transluminal coronary angioplasty (PTCA) is defined as 
balloon angioplasty undertaken as the primary reperfusion strategy for MI without 
previous or concomitant thrombolytic therapy9. Primary PTCA is better than 
thrombolytic therapy at reducing short-term major adverse cardiac events, 
including death in individuals with ST-segment elevation MI. These favourable 
results are sustained during long-term follow up too. Primary PTCA is associated 
with better clinical outcomes than thrombolytic therapy irrespective of the type of 
thrombolytic regimen used9.  
 
Specific considerations: 
a. Primary PCI should be performed as quickly as possible, with a goal of a 
medical contact–to-balloon or door-to-balloon time of within 90 minutes.   
b. If the symptom duration is within 3 hours and the expected door-to-balloon 
time minus the expected door-to-needle time is: 
i) within 1 hour, primary PCI is generally preferred. 
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ii) greater than 1 hour, fibrinolytic therapy (fibrin-specific agents) is 
generally preferred. 
c. If symptom duration is greater than 3 hours, primary PCI is generally 
preferred and should be performed with a medical contact–to-balloon or door-
to-balloon time as brief as possible, with a goal of within 90 minutes.  
d. Primary PCI should be performed for patients younger than 75 years old with 
ST elevation or LBBB who develop shock within 36 hours of MI and are 
suitable for revascularization that can be performed within 18 hours of shock, 
unless further support is futile because of the patient’s wishes or 
contraindications/unsuitability for further invasive care 
e. Primary PCI should be performed in patients with severe CHF and/or 
pulmonary edema (Killip class 3) and onset of symptoms within 12 hours. The 
medical contact–to-balloon or door-to-balloon time should be as short as 
possible (i.e., goal within 90 min).  
 
Primary PCI is reasonable for selected patients 75 years or older with ST 
elevation or LBBB or who develop shock within 36 hours of MI and are suitable 
for revascularization that can be performed within 18 hours of shock. 
 
Patients with good prior functional status who are suitable for revascularization 
and agree to invasive care may be selected for such an invasive strategy.  
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It is reasonable to perform primary PCI for patients with onset of symptoms within 
the prior 12 to 24 hours and 1 or more of the following: 
a. Severe CHF  
b. Hemodynamic or electrical instability  
c. Persistent ischemic symptoms7 
 
If the expected door-to-balloon time exceeds the expected door-to-needle time 
by more than 60 minutes, fibrinolytic treatment should be considered unless it is 
contraindicated. This is particularly important when symptom duration is less than 
3 hours but is less important with longer symptom duration, when less ischemic 
myocardium can be salvaged. 
 
Assessment of the thrombolysis outcome 
The assessment of successful thrombolysis is very important to plan for the next 
immediate step needed. This fact was recognised very early and many people 
have tried to assess the criteria by which a failed thrombolysis can be detected 
early. There have been many criteria that have been used for this purpose. 
 
Relief of chest pain 
Though relief of chest pain was recognised as one of the earliest markers of 
successful thrombolysis, it has many limitations. Although it predicts reperfusion 
with a sensitivity of 66-84% this happens in only 30-50% of patients and the 
specificity marker is below 30%66-68. Chest pain can be diminished or abolished 
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with opiates in many, including those with a persistently occluded vessel. 
Conversely, a persistent ache often occurs in those with an open vessel (possibly 
because of lack of tissue perfusion). As age, diabetes, pain threshold, and the 
development of pericarditis also influence pain, the presence or absence of pain 
is limited as a diagnostic test. The persistence or resolution of symptoms 
therefore does not have good predictive value in determining reperfusion 
status67.  However, consideration of rescue techniques for those with continuing 
ischaemic pain may be one method of targeting those most likely to benefit. 
Since this clinical information is readily accessible and may be of value when 
used in conjunction with other markers30, it is still used commonly to assess 
patients after thombolysis. 
 
ECG criteria 
Many ECG criteria have been examined. These include the ratio of the height of 
maximum ST elevation before and after treatment (usually measured 80 ms after 
the J point), the ratio of sums of ST segment elevation and/or depression, and 
the height of the T wave. The numerous studies investigating the relationship 
between ST segment resolution and patency of the infarct-related artery yield 
sensitivities of 52-97% with specificities of 43-88%69-71.The criterion that appears 
to be most established is failure of the elevated ST segment (measured 80 ms 
after the J point in the lead of the 12 lead ECG with maximal ST elevation at 
baseline) to fall by 50% or more. 
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Equally importantly, a prompt reduction in ST segment shift appears to be 
associated with a better clinical outcome. In GISSI-2 (Gruppo Italiano per lo 
Studio della Sopravivenza nell'Infarcto Miocardico), patients with >80% reduction 
in ST elevation 4 hours after the initiation of therapy had less than half the in-
hospital mortality rate of those with <20% reduction72, while in ISAM (Intravenous 
Streptokinase in Acute Myocardial Infarction) early resolution of ST segment 
elevation was a powerful predictor of both early and late mortality after 
myocardial infarction73. There is consistent relation between degree of ST-
segment resolution after thrombolysis and outcome. In the INJECT trials mortality 
was 17.5% in patients who achieved less than 30% ST segment resolution at 
three hours compared with 25% in those whose ST segments resolved by more 
than 70%74-77. 
 
Continuous ST monitoring using a varying number of ECG leads has been 
studied by several groups. This technique has revealed the very dynamic nature 
of the reperfusion process. ST segment monitoring is attractive in concept as this 
provides a means of assessing peak ST elevation, rather than its baseline level 
just before treatment starts. This could improve accuracy, but additional 
equipment is necessary and results must be available on-line for meaningful 
clinical use. ST segment and QRS vector analysis are other methods under 
evaluation but are not in routine clinical use.  
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Reperfusion arrhythmias are well recognised but are very insensitive for 
prediction of reperfusion. The early and frequent appearance of automatic 
idioventricular rhythm is perhaps the most useful marker of reperfusion and the 
absence of this rhythm can be incorporated as one of several criteria to help 
make the diagnosis of failed reperfusion. 
 
Cardiac enzyme release 
Measurement of cardiac enzyme release had become an integral part of the 
retrospective diagnosis of myocardial infarction, and the peak concentrations are 
useful in the process of risk stratification. In general, though, they have not 
proved very useful for immediate decision making in the management of acute 
myocardial infarction.  A single measurement is not useful and even sequential 
measurements are difficult to interpret as the shape of the release curve relates 
to the time from onset of infarction (which is very variable) and to the thrombolytic 
agent used. There was considerable interest in biochemical tests for diagnosing 
failed thrombolysis. These included creatine kinase isoenzymes78-80, troponin T79 
or I80, fatty acid binding proteins and myoglobin78-80. Despite the high sensitivities 
and specificities described, none of these tests found favour in routine practice or 
were subjected to a prospective analysis in which the results influenced clinical 
decisions. Frequent blood sampling is often required and the determination of 
reperfusion sometimes depends on complex mathematical models. 
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Immunogenecity of Streptokinase 
Streptokinase, a protein produced by beta haemolytic streptococci, is the most 
widely used and least expensive thrombolytic agent. However, a disadvantage to 
its use is its antigenicity due to the widespread presence of antibodies in the 
population, presumed secondary to previous streptococcal exposure or infection. 
The immunogenecity of STK was noted by Tillet and Garner81 shortly after 
discovering its fibrinolytic effect. They found that STK was inactivated in blood 
samples from patients with recent Streptococcal infection as a result of the 
presence of neutralization of antibodies. A measurable level of antibodies to STK 
is nearly omnipresent in the population as a consequence of the high frequency 
of Streptococcal infection11,16. To induce a thrombolytic state, streptokinase must 
neutralise these antibodies as well as the endogenous inhibitors of fibrinolysis. 
 
Studies in the general population in United Kingdom showed that 61% of the 
people had detectable IgG antibodies to streptokinase. However these titres 
varied from 0 to 490 with a median of 7 reflecting that antibody titres were 
generally low. Only a small percentage of subjects (10%) had high titres of 
streptokinase antibodies. No difference was found in the levels of antibody titre 
among different age groups or between sexes82. However this also showed that 
a proportion of the general population who had no previous streptokinase 
treatment could be as much at risk of an immune reaction to streptokinase as 
subjects who had received streptokinase earlier. 
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The prevalence of antistreptokinase antibodies in patients presenting to the 
coronary care unit for the first time is usually low and most are expected to 
respond to a standard dose of streptokinase. However most patients develop 
antibodies and streptokinase resistance by day 7 and upto 75% of patients 
treated once with streptokinase will be resistant to further treatment with 
streptokinase containing agents after two years83. The outcome from retreatment 
with streptokinase containing agents is likely to be unpredictable for a period 
beginning four to seven days after streptokinase dosage and lasting for more 
than two years. Other data suggest that this period may last for at least four 
years84. 
 
A similar high titre of antibody is expected in patients with recent streptococcal 
infection. Presence of such antibodies can have profound effects on the outcome 
of the thrombolytic therapy. Clinical failure of the activation of the fibrinolytic 
system by STK has been reported due to the presence of a high titre of ASTK 
antibodies12. In vitro clot lysis studies have demonstrated a significant reduction 
in the activation of plasminogen by STK between days 6 and 21 following STK 
therapy, a time when antibody titres are known to be high85. The presence of 
specific ASTK IgG antibodies has a major effect on the activity of STK in vitro. 
High circulating antibody titres to STK are likely to influence the efficacy of the 
thrombolytic state achieved, as well as causing the potential problems of adverse 
immune responses86. 
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While it has been shown that the level of anti streptokinase antibodies is 
generally low in the population in western countries, the same does not hold true 
for patients from areas with high endemic streptococcal infections. 
 
It has been shown that there is a significantly higher prevalence of ASTK 
antibodies in indigenous Australian patients with ACS compared with non 
indigenous long term residents (74% v 25%). These indigenous patients were 
concentrated in the, 54 age group, where ASTK antibody titres were highest, and 
mortality was seven to 12 times that of non-indigenous age matched controls17.  
Dramatically elevated anti streptokinase titre have been shown in the general 
aboriginal population in Australia who are subjected to endemic streptococcal 
infections13. 
 
It has been shown that the level of anti streptokinase antibodies in the Indian 
population also is higher. It may take twice the amount of streptokinase to 
neutralise these antibodies, than for the western population. This raises the 
doubt about the efficacy of the dose of SK being used now for thrombolysis in the 
Indian population14. 
 
Similarly, patients who have been exposed to STK earlier are likely to have 
ASTK antibodies that would be expected to neutralise the standard dose of STK. 
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To assess the outcome of presence of anti streptokinase antibodies on 
thrombolysis, many studies have been conducted. These studies have shown a 
varying picture of the response to thrombolysis.  
 
An angiographic study showed that patients with persisting coronary occlusion at 
24 hours tended to have higher anti-SK antibody titres18. However, another study 
from India15 showed no relation between pretreatment ASTK antibody titres and 
reperfusion rates, although basal antibody values were relatively high in all 
patients, suggesting a potential compromise of the action of STK across the 
entire study population. A similar result was shown in another study from 
Pakistan where even though the antibody titre were high, they didn’t seem to 
affect the outcomes of thrombolysis16. 
 
The effect of thrombolysis and its efficacy is hence to be proven beyond these 
doubts. With the introduction of primary PTCA as the treatment of choice for 
STEMI, it needs to be reassessed if the door to balloon time mentioned for the 
western countries holds true in the Indian population. With higher chances of 
failure of thrombolysis, late presentation of patients and the fact that the benefit 
of primary PTCA appears to be the same till a window period of 12 hours, a 
longer door to balloon period may be allowed in the Indian patients, especially 
when they are being planned for a fibrinolytic therapy with streptokinase and are 
likely to have high ASTK antibody titres. 
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MATERIAL AND METHODS 
 
The study was conducted in the Department of Cardiology and Department of 
Microbiology at Christian Medical College (CMC) Vellore. 
 
Patients presenting with acute STEMI to the casualty or the ‘chest pain unit’ were 
enrolled for the study, after an informed consent, if they satisfied the inclusion 
criteria. 
 
Sample size 
A minimum of 80 patients were to be recruited. 40 of these patients were to be 
those presenting within 6 hours of onset of chest pain and 40 with those 
presenting within 6-12 hours of onset of chest pain. However by the end of the 
study period, a total of 148 patients were included in the study. 
 
Inclusion criteria 
1. Patients with first episode of STEMI  
2. Aged between 20-70 years 
3. Presenting within 12 hours of onset of pain with no contraindications for 
thrombolysis 
4. Not willing for a primary PTCA 
5. No history of prior treatment with streptokinase 
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6.  No other associated cardiac pathology like rheumatic heart disease, 
cardiomyopathies and congenital heart disease which could have had an 
effect on the one month survival and other clinical end points. 
 
STEMI was diagnosed in any patient presenting with chest pain or discomfort 
and the electrocardiogram (ECG) showing ST segment elevation greater than 0.1 
mV in at least 2 contiguous precordial leads or at least 2 adjacent limb leads. 
After ascertaining the absence of any contraindications these patients were 
thrombolysed with streptokinase. Those presenting beyond 12 hours duration are 
not recommended routinely for thrombolysis and hence were excluded.  
 
Exclusion criteria 
Since primary PTCA is the treatment of choice for the patients presenting with 
acute STEMI, they were offered this mode of therapy first and only those patients 
who were not willing for the same were enrolled for the study. Any other 
associated comorbities which could effect the clinical outcome if present was 
noted and such patient were excluded from the study. Also those patients who 
presented with cardiogenic shock or those who died within 30 minutes of 
initiation of thrombolytic therapy were also excluded as the outcome of these 
patients was unlikely to have been changed significantly by the thrombolytic 
therapy. 
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Sample collection and assessment of the response 
In all the patients, 3-4 ml of blood was collected at the time of admission before 
the initiation of thrombolysis and was sent to the serology laboratory. The serum 
was further stored at -70o C till the time of analysis for ASTK antibody titres. 
 
All the patients were assessed for the criteria for reperfusion defined as: 
- Resolution of chest pain in less than 90 min after start of thrombolysis 
- Greater than 50% resolution of ST segment elevation in 2 contiguous leads 
showing maximum elevation in a 12 lead ECG taken 60 - 90 min after the 
thrombolytic therapy.  
- Any reperfusion arrhythmia within 90 minutes of the thrombolysis. The 
arrythmias that were considered were accelerated idioventricular or junctional 
rhythm, transient second or third degree AV block not needing pacemaker 
support, acute sinus bradycardia (<50bpm), ventricular tachycardia or 
ventricular fibrillation. 
 
Patients who had all 3 criteria were taken as responders and those with 2 were 
taken as probable responders and those with one or no criteria were taken as 
non responders. 
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Clinical end points – Major adverse cardiovascular events 
The clinical end points were defined a below - 
• Rest angina: The occurrence of any chest pain at rest, suggestive of angina, 
was taken as an episode of rest angina. This was irrespective of having taken 
any ECG during the episode or having taken any blood sample for estimation 
of cardiac enzymes.  
• Heart Failure: Any episode of breathlessness needing hospitalisation and /or 
injectable diuretics for recovery was taken as an episode of heart failure 
unless diagnosed otherwise, provided the patient had documented left 
ventricular dysfunction as demonstrated by echocardiography at discharge or 
at the time of admission for breathlessness. 
• Reinfarction: Any episode of acute chest pain with documented rise in the 
cardiac enzyme level by at least 2 times the normal level with or without new 
ECG changes was taken as an episode of re infarction. 
• Death: Any patient dying without any demonstrable or diagnosed non cardiac 
cause during the period was taken as an episode of death due to cardiac 
cause.  
 
All the patients recruited were counselled about the importance of regular 
medications and follow up. They were also contacted at 15-18 days of the event 
to enquire about the drug compliance and any clinical events. The patients were 
re-examined between 30-40 days of the clinical event and enquired about the 
clinical events at 30 days of the event. Those patients not reporting for review by 
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35 days were again contacted by phone or letter, for the review. All the data was 
collected by the principal investigator. 
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OBSERVATIONS AND RESULTS 
 
Between 1st April 2009 and 28th February 2010 a total of 148 patients with acute 
ST-segment elevation myocardial infarction (STEMI) were enrolled into this 
study. The analysis of the data of these study subjects over a follow-up period of 
30 days are shown below. 
 
Statistical Methods 
Data was entered using MS Excel and analyzed using STATA (STATACORP, 
TX, USA). Continuous variables were described using mean and standard 
deviation, if normally distributed.  Variables which had skewed distribution were 
described using medians with range. The statistical significance of the 
association between the response and ASTK antibody levels was assessed 
using either chi-square test or fisher exact test (when expected cell count is <5). 
P<0.05 is considered as statistically significant.  
 
Demographic data 
Of the total patients almost 90% were males and the rest were females. 
 
Table 1: Sex distribution 
Sex No. of patients Percentage (%) 
Male 133 89.86% 
Female 15 10.14% 
Total 148 100% 
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The mean and median age of the patients was 52 years. 11% of the total patients 
were under the age of 40 years. 
 
Table 2: Mean and median age of the study subjects 
 Mean±SD Median Min Max 
Age (years) 52±9.1 52 26 70 
 
Table 3: Distribution of patients according to age 
Age group No. of patients Percentage (%) 
≤40 years 16 10.81% 
>40 years 132 89.19% 
Total 148 100% 
 
The body mass index (BMI) was calculated for all the patients. The average BMI 
was around 25kg/m2. Nearly 42% of patients were overweight while almost 5% 
were obese. 
 
Table 4: Body mass index range in patients 
BMI (kg/m2) No. of patients Percentage (%) 
<20 8 5.41% 
20-24.9 71 47.97% 
25-29.9 62 41.89% 
≥30 7 4.73% 
Total 148 100% 
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Table 5: Distribution of body mass index (BMI) according to sex 
 n Mean±SD min max 
Male 133 26.5±3.6 21 35 
Female 15 24.9±2.9 18 34 
Total 148 25.11±2.99 18 35 
 
Risk factor analysis 
Of the total patients almost 40% had diabetes mellitus and 37% had 
hypertension. More than 55% of patients were smokers. There were no smokers 
among the females. When taken this into account, 61% of the male patients were 
found to be smokers. 
 
Table 6: Distribution of diabetes mellitus according to sex 
Sex Diabetes mellitus 
Absent Present 
Male 82 (61.65%) 51 (38.35%) 
Female 7 (46.67%) 8 (53.33%) 
Total 89 (60.14%) 59 (39.86%) 
 
Table 7: Distribution of hypertension according to sex 
Sex Hypertension 
Absent Present 
Male 85 (63.91% 48 (36.09%) 
Female 8 (46.67%) 7 (46.67%) 
Total 93 (62.84%) 55 (37.16%) 
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Table 8: Distribution of smoking status according to sex 
Sex Smoking status 
Non-smoker Smoker 
Male 51 (38.35%) 82 (61.65%) 
Female 15 (100%) 0 (0%) 
Total 66 (44.59%) 82 (55.41%) 
 
The analysis of the serum lipid profile showed the following results. The average 
LDL level was 110.39 mg% with a median of 105.5 mg%. The average HDL was 
33.73 mg% with a median of 33.5 mg%. The average TG was 159.14 mg% with 
a median of 129 mg%. 
 
Table 9: Distribution of lipid profile according to sex 
Sex TC (mg/dl) TG (mg/dl) HDL (mg/dl) LDL (mg/dl) 
Male (n=130) 180.91±43.90 159.14±96.73 33.73±7.66 110.39±35.34
Female (n=15) 193.86±62.17 226.86±305.77 40.66±10.59 118.46±36.66
Total (n=145) 182.56±46.11 166.15±133.79 34.44±8.24 111.22±35.44
TC=Total cholesterol, TG=Triglyceride, LDL=Low density lipoprotein, HDL=High density 
lipoprotein 
 
Time of presentation – Window Period 
The average time to presentation after the onset of symptoms, termed the 
window period, was 345.54 min (5 hours, 45min) with a median of 300 min (5 
hours). 46 patients presented directly to our centre with an average window 
period of 168.7 min (2 hours, 48 min). The average window period in the other 
patients was 425.29 min (7 hours, 5 min).  
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Table 10: Window period (in minutes) at presentation 
Sex n Mean±SD Median Min Max 
Male 133 347.78±182.68 300 60 720 
Female 15 325.66±193.73 270 30 660 
Total 148 345.54±183.27 300 30 720 
 
Table 11: Window period (in minutes) in patients presenting directly to us 
and those referred from elsewhere 
 n Mean Min Max 
Presented directly 46 168.70 30 240 
Referred 102 425.29 120 720 
Total 148 345.54 30 720 
 
Table 12: Number of patients with window period ≤6 and >6 hours 
WP No. of patients Percentage (%) 
≤360 94 63.51% 
360+ 54 36.49% 
Total 148 100% 
 
The distribution of STEMI involving different regions was as following: 
Table 13: Myocardial infarction (MI) involving different territories 
MI No. of patients Percentage (%) 
Inferior wall MI 59 40.41% 
Anterior wall MI 84 56.16% 
Lateral wall MI 5 3.42% 
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Drugs prescribed and compliance at 30 days 
The drugs prescribed at discharge were also noted. The prescriptions given for 5 
important drugs was analysed which included aspirin, clopidogrel, a statin, a beta 
blocker and an ACE inhibitor/ ARB (angiotensin receptor blocker). The results 
were as following:  
 
Table 14: Drugs prescribed at discharge 
Drugs No. of patients Percentage (%) 
All drugs – BB 2 1.36% 
All drugs – ACE-I 2 1.36% 
All drugs 142 96.60% 
All drugs – BB – ACE-I 1 0.68% 
BB=Beta-blockers, ACE-I=Angiotensin converting enzyme-inhibitors 
All drugs include aspirin, clopidogrel, ACE-I/angiotensin receptor blocker, statins, beta-blockers 
 
All the patients were also treated with an anticoagulant after thrombolysis. The 
same was prescribed for a minimum of 3 days. The three drugs used were 
Fondaparinux, Enoxaparin and Unfractionated heparin. The ratio of patients who 
received these different drugs was as following: 
 
Table 15: Anticoagulant used 
Anticoagulant No. of patients Percentage (%) 
Fondaparinux 130 87.84% 
Enoxaparin 10 6.76% 
Unfractionated heparin  8 5.41% 
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The patients were followed up for 30 days and assessed for drug compliance. 
The following results were obtained. Almost 95% of the patients who did not have 
a MACE continued all the drugs prescribed to them. 2 patients were lost in follow 
up. 
 
Table 16: Drugs at 30 days of follow-up in patients without MACE 
Drugs No. of patients Percentage (%) 
All drugs 110 95% 
No drugs 6 5% 
Total 116  
 
Antistreptokinase antibody titres 
The antistreptokinase antibody titres were estimated in serial doubling dilutions 
starting from 40. So the titre values obtained were 0, 40, 80, 160, 320, 640, 1280, 
2560, 5120 and 10240. The analysis showed the following results 
 
Table 17: Mean and median anti-streptokinase antibody titres in the study 
subjects  
 Mean±SD Median Min Max 
ASTK 717±1211 320 0 10240 
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Table 18: Distribution of levels of anti-streptokinase antibody titres 
ASTK No. of patients Percentage (%) 
0 - 40 30 20.27% 
80 - 160 32 21.62% 
320 - 640 47 31.76% 
1280 and above 39 26.35% 
 
Patients with one or no criteria for reperfusion were taken as non responders, 
those with 2 markers as probable responders and those with 3 markers as 
responders. The analysis showed that almost 37% of the patients had either one 
or no marker indicating that they were non responders and 63% of the patients 
were either responders or probable responders. 
 
Table 19: Reperfusion markers of thrombolysis in the patients 
Events No. of patients Percentage (%) 
No reperfusion marker 18 12.16% 
1 reperfusion marker 36 24.32% 
2 reperfusion markers 33 22.30% 
3 reperfusion markers 61 41.22% 
 
 
Analysis of the response in relation to the window period showed the following. 
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Table 20: Comparison of different responses to thrombolysis in relation to 
the time of presentation 
Response Window period (min) Total 
≤360 360+ 
Non-responders 19 (35.18%) 35 (64.82%) 54 (36.49%) 
Probable responders 24 (36.72%) 9 (27.28%) 33 (22.30%) 
Responders 51 (83.61%) 10 (16.39%) 61 (41.2%) 
Total 94 (63.51%) 54 (36.49%) 148 (100%) 
 
We chose the median value of ASTK antibody titre as reference point to 
categorize into high titres and low titres. This was done because there was no 
established normal value for the general population and the values had a skewed 
pattern which affected the mean. The median value was 320. 
The response to thrombolysis was analysed in relation to the presence of high 
(320+) titres or low (≤320) titres. 
 
Table 21: Response of thrombolysis in patients with high ASTK antibody 
titres in relation to the time of presentation (Titre > 320+) 
Response Window period (min) Total 
≤360 360+ 
Non-responders 19 (50.0%) 19 (50.0%) 38 
Probable responders 7 (87.5%) 1 (12.5%) 8 
Responders 13 (92.86%) 1 (7.14%) 14 
Total 39 (65.0%) 21 (35.0%) 60 
p=0.006 (Fisher’s exact test) 
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Table 22: Response of thrombolysis in patients with low ASTK antibody 
titres in relation to the time of presentation (Titre ≤320) 
Response Window period (min) Total 
≤360 360+ 
Non-responders 0 (0%) 16 (100%) 16 
Probable responders 17 (68%) 8 (32%) 25 
Responders 38 (80.85%) 9 (19.15%) 47 
Total 55 (62.5%) 33 (37.5%) 88 
p<0.001 
 
In patients who presented with window period of <6 hours, 69% of responders 
had titres ≤320 while 100% of non-responders had a titre of >320. 
 
Table 23: Response to thrombolysis in patients presenting with window 
period ≤360 min (≤6 hours) 
ASTK Response to thrombolysis Total 
Non-
responders 
Probable 
responders 
Responders 
≤320 0 (0%) 17 (30.91%) 38 (69.09%) 55 (100%) 
320+ 19 (48.72%) 7 (17.95%) 13 (33.33%) 39 (100%) 
Total 19 (20.21%) 24 (25.53%) 51 (54.26%) 94 (100%) 
p<0.001 
 
In patients who presented with window period >6 hours, only 48% of patients with 
titres ≤320 were non-responders while 90% of patients with titre >320 were non-
responders. 
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Table 24: Response to thrombolysis in patients presenting with window 
period >360 min (>6 hours)  
ASTK Response to thrombolysis Total 
Non-
responders 
Probable 
responders 
Responders 
≤320 16 (48.48%) 8 (24.24%) 9 (27.27%) 33 (100%) 
320+ 19 (90.48%) 1 (4.76%) 1 (4.76%) 21 (100%) 
Total 35 (64.81%) 9 (16.67%) 10 (18.52%) 54 (100%) 
p=0.007 
 
Further, the ‘responders’ and ‘probable responders’ were grouped as patients 
having benefited from thrombolysis and the ‘non responders’ as not having 
benefited from thrombolysis.  
Further analysis in these two categories showed that, within a window period of 6 
hours, the patients who benefited from thrombolysis were more likely to have 
lower ASTK antibody titres while all the patients who did not benefit had high 
ASTK antibody titres. 
   
Table 25: Benefit of thrombolysis in patients with window period less than 
6 hours (≤360 min) 
ASTK Benefit of thrombolysis Total 
No Yes 
≤320 0 (0%) 55 (73.33%) 55 (58.51%) 
320+ 19 (100%) 20 (26.67%) 39 (41.49%) 
Total 19 (100%) 75 (100%) 94 (100%) 
p<0.001 
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Similarly patients who presented after 6 hours and had benefited from 
thrombolysis were more likely to have lower ASTK antibody titres while more 
than 50% of those who did not benefit, had high titres. 
 
Table 26: Benefit of thrombolysis in patients with window period more than 
6 hours (360+ min) 
ASTK Benefit of thrombolysis Total 
No Yes 
≤320 16 (45.71%) 17 (89.47%) 33 (61.11%) 
320+ 19 (54.29%) 2 (10.53%) 21 (38.89%) 
Total 35 (100%) 19 (100%) 54 (100%) 
p=0.002 
The benefit of thrombolysis in relation to the varying antibody titres also showed 
a significant relation, with patients having titre more than 1280, more likely not to 
have benefited from thrombolysis than those with lower titres. 
  
Table 27: Benefit of thrombolysis in relation to the varying antibody titres 
ASTK Benefit of thrombolysis Total 
No Yes 
0 - 40 8 (26.67%) 22 (73.33%) 30 (100%) 
80 -160 5 (15.63%) 27 (84.38%) 32 (100%) 
320 - 640 12 (25.53%) 35 (74.47%) 47 (100%) 
1280 and above 29 (74.36%) 10 (25.64%) 39 (100%) 
Total 54 (36.49%) 94 (63.51%) 148 (100%) 
p<0.001 
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Risk factors in patients less than 40 years old 
The risk factor analysis was done in a small subgroup of patients who were aged 
less than or equal to 40 years. Though the numbers were small to show any 
statistically significant result, 75% of the patients in this subgroup were smokers. 
The average window period was however shorter in this subgroup compared to 
the total average. 
 
Table 28: Lipid profile and window period in age <40 years (n=16) 
 
Lipids Mean±SD Median Min Max 
LDL (mg/dl) 102.43±22.89 101.5 66 139 
HDL(mg/dl) 35.25±10.46 35.0 21 62 
TG (mg/dl) 172.06±63.79 167.5 94 309 
WP (min) 297.18±186.67 272.5 60 660 
LDL=Low density lipoprotein, HDL=High density lipoprotein, TG=Triglycerides, WP=Window 
period (min) 
 
 
 
 
Table 29: Distribution of common risk factors in patients with age <40 years 
 No. of patients Percentage (%) 
   
Diabetes mellitus 1 6.25% 
Hypertension 2 12.50% 
Smoker 12 75.00% 
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Analysis of the major adverse cardiovascular events 
Patients were followed up for 30 days for any major adverse cardiovascular 
events (MACE). The MACE that were looked for were death, reinfarction, rest 
angina and congestive cardiac failure. 2 patients were lost during follow up. 
 
Table 30: Incidence of major adverse cardiovascular events (MACE) 
MACE No. of patients Percentage (%) 
Absent 116 79.45% 
Present 30 20.55% 
 
The different events which were noted are shown in the table. As seen rest 
angina was the most common MACE of all the four. 
 
Table 31: Different events recorded as MACE at 30 days 
MACE No. of patients Percentage (%) 
Death 5 16.67% 
Reinfarction 4 13.33% 
Rest angina 15 50.00% 
Congestive cardiac failure 6 20.00 
Total 30 100% 
 
The relation of presence of MACE in relation to the time of presentation showed 
that MACE was more likely in those who presented after a window period of 6 
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hours. The numbers were however not enough to give any statistical 
significance. 
 
Table 32: MACE in patients depending on the time of presentation 
MACE Window period (min) Total 
≤360 360+ 
Absent 77 (66.38%) 39 (33.62%) 116 (100%) 
Present 16 (53.33%) 14 (45.67%) 30 (100%) 
Total 93 (63.70%) 53 (36.30%) 146 (100%) 
p=0.185 
 
The occurrence of MACE was further analysed in relation to the presence of low 
or high ASTK antibody titres. This showed that patients without MACE were more 
likely to have low titres and those with MACE were more likely to have high titres. 
This relation was statistically significant. 
 
Table 33: MACE in patients depending on the antistreptokinase antibody 
titres 
MACE ASTK  Total 
≤320 320+ 
Absent 74 (63.79%) 42 (36.21%) 116 (100%) 
Present 13 (43.33%) 17 (56.67%) 30 (100%) 
Total 87 (59.59%) 59 (40.41%) 146 (100%) 
p=0.042 
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Further the MACE was analysed separately in patients with high and low titres 
who had presented before 6 hours and those who presented after 6 hours. In 
both the groups the patients with higher titres were more likely to have MACE 
than those with lower titres.  
 
Table 34: MACE in patients with high and low titres with window period <6 
hours (360 min) 
MACE Window period (min) Total 
≤320 320+ 
Absent 48 (62.34%) 29 (37.66%) 77 (100%) 
Present 6 (37.50%) 10 (62.50%) 16 (100%) 
Total 54 (58.06%) 39 (41.94%) 93 (100%) 
p=0.067 
 
Table 35: MACE in patients with high and low titres with window period >6 
hours (360 min) 
MACE Window period (min) Total 
≤320 320+ 
Absent 26 (66.67%) 13 (33.33%) 39 (100%) 
Present 7 (50.00%) 7 (50.00%) 14 (100%) 
Total 33 (62.26%) 20 (37.74%) 53 (100%) 
p=0.270 
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DISCUSSION 
 
Ischemic heart disease is the leading cause of death in both the developing and 
the developed countries1. The fact that it is estimated to rise further and faster in 
the developing countries is a matter of concern. India is going to have a 
significant proportion of the total number of such cases in the world in the near 
future. As discussed earlier, it has also been shown that in India a larger 
proportion of those with acute coronary syndromes (ACS) present with ST 
elevation myocardial infarction (STEMI) than those in the developed countries6. 
However the vast majority of the population doesn’t have access to the optimal 
hospital care for this acute emergency. While the optimum management needs 
an immediate reperfusion by primary PTCA, there are very limited centres which 
can offer this treatment. The significant majority of the population is treated with 
thrombolytic therapy6. 
 
There are many thrombolytic agents which have been approved for use. The 
fibrin specific agents have a better mortality benefit than STK, saving upto 10 
lives per 1000 patients treated10. However, the fibrin selective agents are many 
times the cost of STK making STK the most commonly used thrombolytic agent 
in most developing countries. However a fact to be noted is that almost all the 
studies that have been done to assess the efficacy of these agents were 
conducted in the western population. It has been proven that the action of 
streptokinase is neutralised in the presence of anti streptokinase 
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antibodies12,13,83,86,87, which are formed in the body in response to the 
streptococcal infections. These infections are very common in the developing 
countries like India and it has been proven in earlier studies that the anti 
streptokinase antibody titres are much higher in the subcontinental population 
than in the developed countries14,16,82. Under these circumstances doubts have 
been raised about the efficacy of streptokinase to treat STEMI12,13,17,19. Studies 
have been conducted earlier to address this concern but they did not give a 
definite evidence and there were too few studies to draw any firm conclusion. 
Also these studies did not take into account the window period at presentation 
which could have also significantly affected the outcome of thrombolysis by 
streptokinase. It is now a well proven fact that the efficacy of thrombolysis 
decreases proportionately with the time duration from onset of symptoms with the 
maximum benefit in the first 2 hours7,42-45. 
 
This study was conducted with a primary objective of assessing the effect of 
ASTK antibodies on the response to thrombolysis and occurrence of MACE while 
taking into account the window period at presentation. The patients were 
analysed in two separate groups with window period less than 360 minutes (6 
hours) and more than 360 minutes. 
 
While planning the study it was thought to enroll a minimum of 80 patients with 
forty each in two groups with window period <360 minutes (6 hours) & 
>360minutes and again at least 20 each in two groups of high & low ASTK 
68 
 
antibody titres. During the course of the study a total of 148 patients were 
enrolled after taking an informed consent. 
 
Demographic results 
Nearly 90% of the patients were males (Table 1). This was similar to the pattern 
seen in the CREATE registry6 in which more than 80% of patients with STEMI 
were males. The increased number could be attributed to two possible factors: 
the proportion of males in patients with STEMI is higher, and also it was noted 
that female patients were more hesitant in giving consent to be part of a study. 
 
Analysis of the different age groups showed that average and median age was 
52 years. There were 16 patients below the age 40 which formed almost 11% of 
the total (Table 2&3). 
 
The body mass index (BMI) analyzed showed that almost 42% of patients were 
overweight and 5% were obese (Table 4).  
 
The risk factors analysis showed that almost 40% of the patients had diabetes 
mellitus and 37% had hypertension (Table 6-9). While the total percentage of 
patients who were smokers was 55%, none of them were females. This showed 
that almost 62% of the male patients were smokers. This proportion is quite high 
from the proportion of patients who were smokers in the CREATE registry. 
However Begom & Singh in 1995 had reported a higher prevalence of smoking in 
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south Indian males which was close to 45%87. Considering that the prevalence of 
smoking has increased over the past decade, this could be taken as the present 
prevalence of smoking among males, especially in the lower socioeconomic 
strata. The prevalence of diabetes mellitus and hypertension was similar to what 
was seen in the previous registry.  
 
The analysis of the lipid profile showed that the mean LDL was 111mg%, HDL 
was 34mg% and triglyceride was 166mg%. All of these values represent 
suboptimal values which can predispose to CAD.  
 
The data was analysed separately in patients with age <40 years to assess the 
risk factors in this subset of young patients (Table 28 & 29). While there was not 
much difference in the prevalence of diabetes mellitus, hypertension or 
dyslipidemia, there was a strikingly high prevalence of smoking in this group. 
75% of the patients in this group were smokers and if the 2 female patients are 
excluded from this, 86% of the male patients were smokers. This shows the 
importance of smoking as an important risk factor for ischemic heart disease, 
especially in the young.  
 
Window period 
Another very important factor affecting the prognosis in patients presenting with 
STEMI is the time of presentation after the onset of chest pain, known as the 
window period7,42-45. The mean window period in our study group was 345min (5 
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hours, 45 min) with a median of 300 min (5 hours) which is longer than what is 
seen in the developed countries4. 21 patients had presented within a window 
period of 3 hours which was only 14% of the total. Almost 64% of the patients 
presented within 6 hours of onset of pain. Only 46 patients had presented directly 
to our centre and the rest of the 102 patients were referred from some other 
hospital (Table 10,11,12). In patients who presented directly to us, the mean 
window period was 168 min (2 hours, 48 min) with a range of 30-240 min. While 
the mean window period of the patients who were referred from elsewhere was 
425 min (7 hours, 5 min) with a range of 120-720 min. The history taken from 
these patients suggested that most of the delay was due to time taken up for 
referral from the peripheral hospital and the travel time. The first medical contact 
of most of the patients was much shorter than the actual window period of 
thrombolysis. This is a striking observation as the mean window period differed 
by more than 4 hours. This shows that a lot of mortality and morbidity can be 
decreased if the importance of early thrombolysis and prompt referral is 
reinforced in the primary physicians who are often the first medical contact of the 
majority of the patients. 
 
Of the total patients, 56% had anterior wall STEMI, while 40% had inferior wall 
MI, with varying combination of right ventricular MI and posterior wall 
involvement, and only 4% were diagnosed to have an isolated lateral wall MI.  
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Compliance with drugs at 30 days 
All the patients were counselled regarding regular medical therapy. The 
prescription pattern of 5 important drugs was also analysed which included 
aspirin, clopidogrel, a statin, betablocker and an ACE inhibitor/angiotensin 
receptor blocker (Table 14-16). 97% of the patients were prescribed all the 5 
essential drugs. Of the patients who did not have any major adverse 
cardiovascular events (MACE), 95% of the patients continued to take the 
treatment as advised, 5% had stopped the prescribed medications and 2 patients 
were lost to follow up. This showed the possible beneficial effect of spending a 
few minutes extra on counselling the patients about the importance of drug 
compliance. The high compliance could have also been due to the close follow 
up of these patients acting as intermittent reminders for drug compliance.  
 
All the patients were also given anticoagulant therapy for at least 3 days post 
thrombolysis. The majority of the patients received Fondaparinux for this 
purpose. 
 
Anti streptokinase antibody titres 
The ASTK antibody levels were assessed by particle agglutination method using 
a commercial kit, SERODIA – ASK, supplied by FUJIREBIO, Tokyo, Japan. The 
method used in earlier studies to assess the ASTK antibody levels included the 
clot  lysis  assay which is a highly sensitive method to measure  the  
streptokinase-neutralising  capacity  in  serum and  an  enzyme-linked  
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immunoassay  (EIA)  to  measure streptokinase-binding  IgG. The particle 
agglutination method has been assessed in comparison to the earlier methods 
and has correlated well with serum neutralising capacity88.  
 
The mean anti-streptokinase antibody levels were 717±1211, however, the range 
varied from minimum of 0 to a maximum of 10240 (Table 17). Since the extreme 
values were affecting the average ASTK antibody titre, it was decided to take the 
median value of 320 units as the reference point. Patients with titres ≤320 were 
taken as having low titres and those with >320 were taken as high titres.  
 
Patients were assessed for the clinical evidence of reperfusion which were 
defined as 
- Resolution of chest pain in less than 90 min after start of thrombolysis 
- Greater than 50% resolution of ST segment elevation in 2 contiguous 
leads showing maximum elevation in a 12 lead ECG taken 60-90 min after 
the thrombolytic therapy. 
- Any reperfusion arrhythmia within 90 minutes of the thrombolysis 
 
Patients who had all 3 criteria were taken as responders and those with 2 criteria 
were taken as probable responders and those with one or no criteria were taken 
as non responders. 
Of the total patients, 61 (41.21%) were responders, 33 (22.3%) were probable 
responders and 54 (36.49%) were non responders (Table 20). These results 
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confirm to those reported earlier from the Indian subcontinent by Shaila et al15 
(48% responders, 28% probable responders and 28% non responders) and 
Kazmi et al16 (42% responders, 37% probable responders and 21% non 
responders). The percentage of non responders in our study appeared to have 
been more than those in these two studies. This could have been due to the fact 
that the ASTK antibody titres are higher in the south Indian population as shown 
earlier by Alexander et al14. 
 
Effect of time 
The effect of time was also analysed in patients with high and low ASTK antibody 
titres (Tables 21 &22). More than 90% of the responders with high titres had 
presented before 6 hours. Similarly in patients with low titres, more than 80% of 
the responders presented before 6 hours while all the non responders presented 
after 6 hours. This showed that patients were more likely to respond to 
thrombolysis when they present early to the hospital independent of the presence 
of low (P<0.001) or high (P=0.006) ASTK antibody titres. This reinforces the 
already known fact that time is a very important factor in the management of 
STEMI and the patient needs to receive a reperfusion therapy at the earliest. 
 
Effect of titre 
The response to thrombolysis was analyzed in subjects presenting before and 
after 6 hours window period and the effect of titre on the response was assessed 
(Tables 23 & 24). In patients with a window period of <6 hours 75% of 
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responders had titres ≤320. Further, of all patients with titres ≤320, 69% of 
patients were responders, which was significantly higher than in patients with 
titres >320 in which only 33% of patients were responders. Of the non-
responders, all the patients (100%) had titres of >320 (p<0.001). In the group of 
patients with a window period >6 hours, among patients who had a titre of >320, 
90% were non-responders, while among those with titres <320, 48% patients 
were non-responders (p=0.007). This shows that irrespective of the window 
period, ASTK antibody titres impaired thrombolysis. The effect was particularly 
pronounced and highly significant in patients who presented with a window 
period of <6 hours and had high titres. This represents a group at significant loss 
who, inspite of presenting early to the hospital have an inadequate response to 
treatment with streptokinase because of high ASTK antibody titres. 
 
Patients were divided into 2 groups for further analysis. ‘Non responders’ were 
grouped as having not benefited from thrombolysis and ‘responders’ and 
‘probable responders’ were grouped as having benefited from thrombolysis. The 
effect of the ASTK antibody titres was analysed in two separate groups with 
window period less than 6 hours and window period more than 6 hours (Tables 
25, 26 & 27).  
 
In the patients with window period <6 hours, 73% of those who benefited from 
thrombolysis had titres less than or equal to 320 while only 27% had titres more 
than 320. All the patients who did not benefit from thrombolysis had high titres of 
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>320 (P <0.001). In patients who had a window period of > 6 hours, 89% of those 
who benefited from thrombolysis had low ASTK antibody titres and almost 54% 
of those who did not respond had high titres (P=0.002). 
 
When the benefit of thrombolysis was assessed in different groups with varying 
titres of ASTK antibodies, it was seen that more than 75% of the patients in each 
group of ASTK antibody titre upto 640 had benefited from thrombolysis while 
almost 75% of patients with titres of 1280 or above had not benefited from 
thrombolysis (P<0.001) ( Table 27). 
 
These results are similar to those observed earlier by Juhlin et al. They also 
showed that an elevated anti streptokinase titre was present in patients without 
signs of reperfusion.  The failure of reperfusion could be due to the neutralization 
of streptokinase by the antibodies in the serum. This has also been shown by 
Urdahl et al13 in the rural aboriginal community in Northern Australia where the 
high anti streptokinase titres in some cases were sufficient enough to neutralize 
the conventional dose of 1.5 million units streptokinase. The population studied in 
their study had high incidence of endemic streptococcal infection resulting in the 
high antibody titres. 
 
Buchalter et al83 have also shown that patients who are treated with 
streptokinase once, develop higher titres of anti STK antibodies leading to 
resistance to subsequent retreatment with streptokinase upto 24 months. Patel et 
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al89 have shown presence of anti streptokinase antibodies in the serum upto 866 
days after having been treated with streptokinase for STEMI.  Lynch et al87 
similarly showed that treatment with streptokinase is unlikely to induce an 
effective thrombolytic state in patients with high ASTK antibody titres. Numerous 
other studies also support these observations12,17,18,86. The ACC/AHA guidelines 
mention the exposure to streptokinase, 5 days before the day of presentation, as 
a relative contraindication for thrombolysis with STK7. 
 
Our study results however vary from the earlier studies by Shaila et al15 and 
Kazmi et al16 who showed no effect of anti streptokinase antibodies on 
reperfusion. However in the study by Shaila et al the total number of patients who 
underwent thrombolysis was 25. This could have been a small number to assess 
the actual effect of ASTK antibody titres on benefit of thrombolysis. In the study 
by Kazmi et al, the window period of the patients undergoing thrombolysis was 
not taken into factor. As has been proven earlier and also evident from our study, 
the window period has a significant effect on the outcome of thrombolysis in 
patients with both high and low titres. Our study showed that the response to 
thrombolysis is impaired in patients with high ASTK antibody titres in patients 
with shorter as well as longer window period. The rates of reperfusion and benefit 
from thrombolysis was significantly higher in patients with low titre than in high 
titre. 
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Our study shows that presence of ASTK antibodies significantly affects the 
outcome of thrombolysis in patients with acute STEMI presenting both before or 
after a window period of 6 hours. A significant proportion of the population in 
developing countries like India is likely to have a high titre of anti streptokinase 
antibody titres, in view of the high incidence of streptococcal infection in the 
population. The efficacy of streptokinase in patients with STEMI and high ASTK 
antibody titres may be doubtful thus affecting the outcome in a significant 
proportion of the patients. 
 
In view of these findings there needs to be a rethink in using streptokinase as the 
first line of thrombolytic agent. It may be preferable to use fibrin specific agents 
like alteplase, tenecteplase or reteplase. These agents have shown better 
outcomes than STK, as discussed earlier, in the western population which is 
likely to have low ASTK antibody titres. The benefit of these agents in a 
population with high ASTK antibodies will be expected to be much more than 
reported earlier.  
 
Though it needs a larger comparative study, our study prompts us to think that 
instead of thrombolysis with STK, in patients with high ASTK antibody titres, it 
may be worthwhile to shift the patient for primary PTCA when there is not an 
undue delay in the process and a fibrin selective agent is not available. The 
current recommendation of a maximum allowable time difference of 60 minutes 
between door to needle & door to balloon time may be relaxed. Though we are in 
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no position to recommend a particular duration that can be allowed, it may be 
worth conducting a trial to compare the results between thrombolysing with 
streptokinase and doing a primary PTCA with a longer door to balloon time 
allowed in patients with high ASTK antibody titres. However if the primary centre 
can thrombolyse with a fibrin specific agent, it should be preferred to a delayed 
primary PTCA. 
 
Finally if a kit for rapid analysis of the level of anti streptokinase titres can be 
developed, it may help us in deciding the thrombolytic agent to be used. This kit 
may also be useful in stratifying patients so that those with low titres may be 
thrombolysed with streptokinase while those with high titres may be planned for a 
primary PTCA. 
 
Major adverse cardiovascular events 
Another important part of our study was to follow up the patients and assess the 
occurrence of major adverse cardiovascular events (MACE) at 30 days of STEMI 
(Table 30 &31). The MACE that were looked for included either death, 
reinfarction, rest angina or congestive cardiac failure (CCF). Of the total 148 
patients, 146 patients were followed for 30 days and 2 were lost in follow up. 30 
patients had a MACE which formed 21% of the total individuals. 50% of the total 
MACE was because of rest angina, almost 20% due to CCF, 17% due to death 
and 13% because of reinfarction. The number of deaths in the entire cohort was 
5 which amounted to a 30 day mortality rate of 3.5%. This was much less than 
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what has been observed in other registries. This could be due to the fact that this 
study was not designed to assess the mortality in patients with STEMI and many 
patients were excluded from the study because of the strict inclusion criteria. As 
a result a relatively low risk subset of patients only must have been part of this 
study. 
 
Analysis of MACE in relation to window period (Table 32) showed that among the 
patients who had a MACE, 47% had presented after 6 hours while in those 
without a MACE only 34% had presented after 6 hours (P=0.18). This showed 
that more number of patients with MACE had presented with a longer window 
period. More numbers may be needed to show the statistical significance of this 
observation. 
 
When a relation was sought between anti streptokinase titres and MACE, it was 
seen that almost 57% of patients with MACE had titres of >320 while only 36% of 
patients without MACE had similar titres (P=0.042). It was hence evident that the 
patients with higher ASTK antibody titres were more likely to have a MACE 
(Table 33). This could be an indication of the higher chances of failure of 
thrombolysis in this group. It also shows that ASTK antibody titres can act as a 
prognostic marker for the adverse outcomes in patients of STEMI who are 
thrombolysed with streptokinase. These patients may then warrant more 
attention than the others. 
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To account for the effect of the window period on the MACE, the MACE was 
analysed in two separate groups with window period <6 hours and >6 hours and 
the effect of high and low antibody titres was assessed (Table 34&35). In patients 
with window period less than 6 hours, almost 63% of those with MACE had titres 
of >320 while only 38% of those without MACE had a similar titre (P=0.067). In 
patients with window period more than 6 hours 50% of those with MACE had 
titres > 320 while 33% of those without MACE had similar titres (P=0.27). In both 
the subgroups the relationship of higher MACE with higher ASTK antibody titres 
appeared to have been preserved though the numbers in individual groups were 
not enough to give a statistical significance.  
 
Our results showed a significantly higher incidence of MACE in patients with high 
anti streptokinase titres. The other studies conducted previously had not 
assessed the clinical outcome and this was a very important outcome seen in our 
study. The effect seemed to be especially more evident in the group with window 
period of less than 6 hours. This group is expected to have a better response in 
view of the shorter time to thrombolysis but the results show that presence of 
anti- streptokinase antibodies may impair the advantage of a shorter window 
period. An indication of higher antibody titres in those with MACE remained in 
those with window period of >6 hours too, though it was not statistically 
significant. However, the results seem to imply that the presence of high anti 
streptokinase titres act as a poor prognostic factor for any given patient with a 
higher chance of developing MACE in the following 30 days. 
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SUMMARY AND CONCLUSIONS 
 
• The mean window period at presentation in patients with STEMI is longer 
in India. 
• Patients presenting directly to the treating hospital had mean window 
period of 2 hours 48 minutes 
• Significant amount of time was lost in patients who were referred for 
treatment with the mean window period being 4 hours more than patients 
presenting directly. 
• Smoking is a very important risk factor in the male patients, especially 
those below the age of 40 years. 
• Anti streptokinase antibodies are widely prevalent in the general 
population 
• These antibodies when present in high titres impair the reperfusion effect 
of streptokinase 
• Patients who responded to thrombolysis were more likely to have low anti 
streptokinase titres while the non-responders had higher titres. 
• The benefit of thrombolysis was significantly better in patients with low anti 
streptokinase titres compared to those with high titres. 
• This pattern was seen in both patients presenting before and after a 
window period of 6 hours. 
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• The effect of high titres was particularly evident in patients who presented 
before 6 hours. In these patients the advantage of early presentation is 
partially lost by the high anti streptokinase titres. 
• There was a significant effect of time on reperfusion by thrombolysis. 
Those presenting early were more likely to respond to thrombolysis than 
those presenting late. 
• There was a direct correlation between high anti streptokinase titres and 
occurrence of major adverse cardiovascular events (MACE). 
• Patients with MACE were more likely to have high anti streptokinase titres 
than those without MACE. This trend was evident in both patients 
presenting before and after 6 hours window period. 
• The anti streptokinase titres can hence be used as a prognostic marker in 
patients presenting with STEMI & treated with streptokinase. 
• High ASTK antibody titres blunt the response to thrombolysis and act as a 
poor prognostic marker in patients with STEMI who are treated with STK. 
Fibrin specific thrombolytic agents like alteplase, reteplase and 
tenecteplase may be preferable for thrombolysis, especially in those who 
are from areas with high endemic streptococcal infections. 
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Abbreviations 
ACS   -   Acute coronary syndrome 
ASTK   -   Anti streptokinase  
CAD       -   Coronary artery disease 
CVD    -   Cardiovascular disease 
STEMI  -   ST segment elevation myocardial infarction 
PTCA  -   Percutaneous transluminal coronary angioplasty 
STK  -   Streptokinase 
ECG  -   Electrocardiogram 
WHO  -   World Health Organisation 
IHD   -   Ischemic heart disease 
MI  -   Myocardial Infarction 
LV  -    Left ventricle 
PCI  -    Percutaneous coronary intervention 
t- PA  -    Tissue type plasminogen activator 
LBBB  -    Left bundle branch block 
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Abbreviations used in the master chart 
Hosp N - Hospital number 
Name  - Name of the patient 
Sex  - Patient gender ( 0- male , 1- female) 
Age   - Age of the patient in years 
Weight - Weight in kilograms 
Height  - Height in meters 
RES   -          Resolution of the ST segment by >50% ( 0 – No resolution,  
1  - resolution present) 
REL          -       Relief from chest pain within 90 minute of thrombolysis  
(0– No relief,  1- Relief present) 
ARRY  - Reperfusion arrhythmias (0- absent, 1- present) 
RESP  -         Response to thrombolysis ( 0,1 – non responders, 
           2 – probable responders, 3 – responders) 
WP  - Window period ( in minutes) 
DM  - Diabetes mellitus (0- absent, 1- present) 
HTN  - Hypertension (0- absent, 1- present) 
Smoker - Smoking status (0- non smoker, 1- smoker) 
TC    - Total cholesterol ( in mg/dl) 
TG  - Triglycerides ( in mg/dl) 
HDL    - High density lipoproteins ( in mg/dl) 
LDL  - Low density lipoproteins ( in mg/dl) 
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MI    -   Area involved in myocardial infarction ( 0 – Inferior wall STEMI,  
                1- anterior wall STEMI, 2- lateral wall STEMI ) 
Drug    -  Drugs prescribed at discharge (  5 - All 5 essential drugs , 0 – beta 
                blocker not given, 1 – ACE inhibitor/ ARB not given, 15 – both beta  
               blocker and ACEI/ARB not given) 
F/C     - Anticoagulant used ( 0- Fondaparinux, 1- Enoxaparin, 2-  
              Unfractionated  heparin) 
30 d    - Drug compliance at 30 days ( All 5 essential drugs – 5, 0 – beta 
               blocker not given, 1 – ACE inhibitor/ARB not given, 15 – both beta 
               blocker and  ACEI/ARB not given) 
MACE  -  Major adverse cardiovascular event 
Event   -  MACE that occurred (0 – death, 1- reinfarction, 2- rest angina, 3-  
                  congestive  cardiac failure) 
ASTK   -  Anti streptokinase antibody titres 
CMC   -  first medical contact ( 1- presented directly to our centre, 0- referred 
               from elsewhere)           
 
 
 
 
 
 
 
 
99 
 
 
STUDY  Proforma 
 
Patient Hospital No:____________     
  
Drug:    ______________________                   
 
Name    :    Sex:  M                  F 
 
Age    :  
 
Address   :       
         Phone No:   
Height:   Weight:     
 
Date of STEMI  : 
 
Window period  : _______ hours. 
 
If > 3 hours, reason for delay : Ignored pain 
‐  Went to local hospital and referred  
‐  Travel > 90mins 
‐  Any other 
‐ Diabetes Mellitus                            Hypertension                                    Smoking 
 
Socio-Economic Status:    - Monthly Income 
              < Rs.2,000/-      Rs.5,000/- to Rs.10,000/- 
 
                 Rs.2,000/- to Rs.5,000/-                                          >Rs.10,000/- 
 
Educational Status: 
 
Self     Un educated / Matriculation   Immediate Attender  Un educated / Matriculation 
    Undergraduate       Undergraduate 
    Post - graduate       Post - graduate 
 
ECG diagnosis    - 
 
ST elevation in    - 
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Response to thrombolysis: 
1. Resolution of ST segment elevation by >50% in 2 contiguous leads       Yes                     
No   
2. Relief from pain within 90min of thrombolysis         Yes         No   
3. Reperfusion arrhythmia                                 Yes         No   
   VT      VF  AV Block         S. Bradycardia          
 
    Others 
 
Adverse Event: 
 
 Hypotension   Bleeding   Anaphylaxis 
 
  Any other  ___________________________________________ 
 
 
Echo Cardiographic Findings 
Echo 
Cardiographic 
At Discharge After 1 month 
LVEF   
E   
A   
E/A   
DECT   
MR   
 
Review at 15th day 
 
‐ Any  hospital admission  Yes   No 
‐ Rest angina     Yes   No 
‐ Heart failure     Yes   No 
‐ Reinfarction     Yes   No 
‐ Death     Yes   No 
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Drugs 
 
Drugs At Discharge After 1 month 
 Aspirin   
Clopidogrel   
Statins   
ACE Inhibiters    
ARBs   
B – Blockers   
Fondaparinux   
Enoxaparin   
Others 
 
  
 
Review after 30 days. 
 
‐ Any  hospital admission  Yes   No 
‐ Rest angina     Yes   No 
‐ Heart failure     Yes   No 
‐ Reinfarction     Yes   No 
‐ Death     Yes   No 
 
 
Dr. Subhendu. 
 
 
 
 
102 
 
Hosp No  Name  Sex  Age  WEIGHT  HEIGHT  RES  REL  ARRY  RESP  WP  DM  HTN  SMOKER  TC  TG  HDL  LDL  MI  Drug  F/C 
30 
d  MACE  Event  ASTK  CMC 
415175d  Velayutham  0  61  69  1.8  1  1  0  2  240  1  1  1  108  87  22  65  1  5  2  5  0     0  1 
129225b  Niyaz S k  0  42  80  1.74  1  1  0  2  225  0  0  1  143  67  29  94  0  5  1  5  0     80  1 
082405b  Kuppuswamy  0  66  73  1.64  1  1  1  3  90  1  1  1  197  78  30  149  2  5  1  5  0     0  1 
423817d  Damodaram  0  64  70  1.59  1  1  0  2  390  1  1  1  100  70  23  59     5  0  5  0     160  0 
478548d  Sampath Raj  0  56  70  1.56  1  1  1  3  300  0  0  1  144  233  23  77  0  5  0  5  0     320  0 
480495d  Ravichandran  0  48  66  1.56  1  1  1  3  60  0  0  0  192  98  39  106  1  5  0  5  0     160  1 
432035d  Selvam R  0  65  52  1.65  1  1  1  3  60  0  0  1  159  85  33  102  0  5  0  5  0     160  1 
432124d  Selvam C  0  37  65  1.65  1  0  0  1  240  0  1  1  122  105  21  78  0  5  0  5  1  2  1280  0 
417772d  Manohari  1  55  57  1.52  0  1  0  1  660  1  1  0  228  135  39  166  0  5  2  5  0     320  0 
418899d  Kannammal  1  54  57  1.55  1  1  0  2  170  0  1  0  168  119  35  105  1  5  0  5  1  3  640  1 
432217d  Lakshmi  1  65  65  1.61  0  0  1  1  420  0  1  0  257  165  39  194  1  5  0  5  1  1  40  0 
480316d  Veeraswamy  0  56  68  1.64  1  1  1  3  120  0  0  1  205  95  34  134  0  5  0  5  0     320  1 
480312d  Ravi Shankar  0  50  72  1.74  1  1  1  3  360  0  0  1  157  161  23  90  0  0  0  6  0     80  0 
484019d  Iqbal  0  26  78  1.62  0  0  0  0  410  0  0  1  220  172  32  134  1  5  0  5  0     160  0 
436093d  Ramamoorthy  0  67  80  1.64  1  1  1  3  240  1  1  1  217  73  45  153  1  5  0  5  0     320  1 
432233d  Jaganathan  0  37  68  1.65  0  1  1  2  540  0  0  1  171  230  38  100  1  5  0  5  0     320  0 
616346d  Annamalai  0  60  71  1.72  1  0  0  1  240  0  0  0  150  77  26  101  2  5  0  5  0     640  0 
432185d  Nagarajan  0  55  50  1.65  0  1  0  1  660  0  0  0  193  118  40  124  1  5  0  5  0     0  0 
432352d  Kamalanathan  0  44  68  1.58  0  1  0  1  420  0  0  1  243  150  38  173  1  5  0  5  0     80  0 
436106d  Kesavel  0  65  76  1.68  0  1  0  1  660  1  0  1  272  106  41  212  1  5  0  5  0     40  0 
439184d  Shyed Naseer  0  46  65  1.68  1  1  1  3  240  0  1  1  157  265  26  87  1  5  0     1  0  0  0 
295455d  Damodaran  0  46  66  1.68  1  0  0  1  540  0  1  1  201  249  31  137  0  5  0  5  0     640  0 
439173d  Sampath  0  44  75  1.63  1  1  1  3  300  0  0  1  200  117  35  135  2  5  0  5  0     80  0 
419162d  Arumugam  0  55  59  1.65  0  0  0  0  240  0  1  1  182  166  35  112  1  5  0     1  0  2560  1 
420877d  Rajendran  0  47  74  1.74  1  1  1  3  420  1  0  1  256  246  38  168  1  5  0  5  0     320  0 
757968c  Illal  1  43  65  1.66  1  1  0  2  300  0  1  0  166  94  29  99     5  0  5  0     320  0 
425404d  Devaraj  0  52  70  1.65  1  1  1  3  180  0  0  1  238  322  34  164  0  5  0  5  0     320  1 
428007d  Venkatachalam  0  62  72  1.7  1  1  0  2  240  1  0  1  126  280  22  60  1  5  2  5  0     320  1 
469566d  Dayalan  0  50  70  1.66  1  1  0  2  225  1  1  0  245  196  39  167  1  5  0  5  0     320  1 
469053d  Raji  0  37  64  1.58  1  1  0  2  300  0  0  1  142  109  35  72  0  5  0  6  0     80  0 
432098d  Murali  0  51  72  1.64  0  0  1  1  480  0  1  0  153  75  28  105  1  5  0     1  2  0  0 
103 
 
429004d  Murugesan  0  60  68  1.54  1  1  1  3  240  1  1  1  177  105  25  128  1  5  2  5  0     80  0 
757536a  Selva Arasu  0  42  69  1.65  1  1  1  3  420  0  0  0  329  85  38  238  1  5  0  5  0     0  0 
429075d  Venkatachalam  0  55  62  1.6  1  1  0  2  180  0  0  0  199  209  30  124  1  5  2  5  0     320  1 
482884d  Sagadevan  0  62  64  1.68  1  1  1  3  120  1  0  0  198  93  36  123  1  5  0  5  0     40  1 
465650d  Radhakrishnan  0  56  66  1.66  1  1  0  2  360  1  0  1  185  268  32  118  1  5  2  6  0     320  0 
472172d  Arunagiri  0  65  64  1.6  1  1  1  3  170  0  0  0  149  82  29  93  1  5  0  5  0     80  1 
483114d  Muthukrishnan  0  65  78  1.62  1  1  1  3  300  0  1  0  164  274  31  82  1  5  0     1  0  0  0 
493531d  Dakshinamoorthy  0  63  68  1.58  1  1  1  3  120  0  0  0  187  99  44  111  1  5  0  5  0     80  1 
004300d  Sundaramoorthy  0  55  70  1.68  1  1  0  2  240  1  0  0  219  119  44  138  0  5  0     1  2  0  0 
608096d  Kanagaraj  0  49  62  1.7  1  0  0  1  300  0  0  1  185  106  42  117  1  5  0     1  2  1280  0 
615789d  Kanniyan  0  59  64  1.64  1  0  0  1  300  1  1  0  181  262  27  103  0  5  0  5  0     1280  0 
508461d  Ekambaram  0  60  65  1.68  1  1  1  3  230  0  1  1  188  74  32  143  0  5  0  5  0     80  1 
518620d  Syed Farook  0  49  68  1.59  1  1  1  3  300  0  1  1  183  115  38  108  1  5  0  5  0     320  0 
526113d  Shankar  0  42  71  1.69  0  0  0  0  360  1  1  1  193  394  20  104  1  5  0  5  0     1280  0 
289227c  Julius  0  49  50  1.55  1  1  0  2  230  1  0  1  184  121  47  108  1  5  0  5  0     320  1 
526258d  Dasarathan  0  56  76  1.71  1  1  1  3  170  0  1  1  159  208  25  91  1  5  0  5  0     640  1 
530059d  Elavazhagan  0  45  58  1.54  1  0  0  1  300  1  0  1  245  428  30  132  0  5  0  5  0     640  0 
530321d  Kandasamy  0  47  64  1.66  1  1  0  2  300  0  0  1  173  182  37  101  1  5  0  5  0     160  0 
530402d  Muthukuruppan  0  59  63  1.64  1  1  1  3  180  0  0  1  172  96  34  100  1  5  0  5  0     320  1 
533115d  Venugopal  0  48  70  1.73  1  1  1  3  180  0  1  1  196  77  35  125  0  5  0  5  0     640  1 
535438d  Sasikala  1  37  62  1.51  1  1  1  3  660  0  0  0  200  109  45  123  1  5  0  5  0     0  0 
535445d  Mariamma  1  56  68  1.58  1  1  0  2  530  1  0  0  148  90  49  78  0  5  0  5  0     0  0 
540051d  Abdul Basheer   0  58  68  1.59  0  0  0  0  660  1  1  0  169  127  37  101  0  5  0     1  0  1280  0 
591412d  Perumal  0  55  77  1.79  1  1  1  3  230  0  1  0  154  113  46  81  0  5  0  5  0     640  1 
591698d  Jeyakumari (F)  1  60  62  1.54  1  1  1  3  30  1  0  0  153  38  51  83  0  5  0     1  2  320  1 
601180d  Boopalan Kg  0  67  59  1.64  0  0  0  0  480  1  0  0  226  130  35  136  1  5  0  5  0     640  0 
602217d  Nandagopal  0  52  80  1.66  0  1  1  2  660  1  1  1  143  129  39  78  0  5  0     1  2  640  0 
554238d  Arumugam  0  44  64  1.71  1  1  1  3  240  0  0  1  207  135  40  135  0  5  0  5  0     0  1 
582097d  Gowthaman  0  48  75  1.68  1  1  1  3  720  0  0  1  253  261  42  180  1  5  1  5  0     80  0 
582064d  Loganathan  0  54  55  1.68  1  1  0  2  420  0  0  1  98  65  22  58  0  1  0  1  0     80  0 
850868C  Narayanaswamy  0  46  59  1.62  1  1  1  3  420  0  1  1  170  120  35  97  0  5  0  5  0     0  0 
582095d  Manivelan  0  44  60  1.65  1  1  0  2  720  0  0  1  217  132  43  143  1  5  0  5  0     320  0 
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563649d  Saravanan  0  36  72  1.69  1  1  1  3  300  1  0  1  111  101  23  67  0  5  0  5  0     640  0 
577369d  Shameem  1  60  63  1.54  1  1  1  3  180  1  1  0  162  82  31  112  1  5  0  5  0     1280  1 
577200d  Lakshmanan  0  59  75  1.6  0  0  0  0  590  1  0  0  156  104  29  91  0  5  0  5  0     1280  0 
577179d  Abdul Khader  0  64  75  1.68  0  0  0  0  540  1  1  0  206  133  30  145  1  5  0  5  0     0  0 
577154d  Babu s m  0  55  77  1.55  1  1  1  3  170  1  0  0  136  149  25  79  0  5  0  5  0     1280  1 
577131d  Abdul Majid  0  69  52  1.56  1  1  0  2  180  1  1  1  139  73  55  64  0  5  0  5  0     0  0 
616228d  Mohan  0  61  56  1.61  1  1  1  3  330  0  1  0  141  91  39  81  1  5  0  5  0     0  0 
577459d  Duraiswamy  0  50  62  1.64  1  1  1  3  180  0  0  1  284  175  28  192  0  15  0  15  0     1280  1 
577430d  Radhakrishnan  0  55  78  1.72  1  1  1  3  110  0  0  1  175  122  26  105  0  5  0  5  0     0  1 
613108d  Sampath  0  45  74  1.71  1  0  0  1  480  0  0  1  103  60  34  55  0  5  0  5  0     2560  0 
577438d  Gopal  0  45  74  1.68  1  0  0  1  420  0  0  0  152  232  29  81  1  5  0  5  0     1280  0 
511154d  Balakrishnan  0  60  63  1.55  0  1  0  1  720  0  1  0  141  94  28  83  1  5  0  5  0     80  0 
508443d  Shanmuganathan  0  28  69  1.59  0  1  0  1  290  0  0  1  183  132  36  118  1  5  0  5  0     640  0 
526345d  Lakshmi k c  1  56  64  1.71  1  1  1  3  270  0  0  0  223  146  49  129  0  5  0  5  0     40  0 
831592a  Vasanthan  0  62  73  1.7  1  1  1  3  240  1  1  1  156  100  32  89  0  5  0  5  0     320  1 
577024d  Srinivasan  0  50  89  1.7  0  0  0  0  720  0  0  0  195  349  37  108  0  5  0  5  0     1280  0 
572465d  Saleem Ahmed  0  42  76  1.68  1  1  1  3  420  0  0  1  171  84  32  114  1  5  0  5  0     40  0 
541705d  Amavasaikannu  0  50  48  1.6  1  1  1  3  290  0  0  1  145  103  44  69  1  5  0  5  0     80  0 
540204d  Dharani S  0  47  62  1.58  1  1  0  2  180  0  1  0  193  142  33  121  0  5  0     1  3  2560  1 
549189d  Narasimhan P  0  50  54  1.58  1  1  1  3  300  0  0  0  167  178  38  93  1  5  0     1  2  160  0 
540266d  Munaf   0  61  76  1.68  1  1  1  3  660  0  0  1  223  117  35  148  0  5  0  5  0     160  0 
544573d  Sekaran  0  65  50  1.56  1  1  1  3  120  1  0  0  198  102  44  119  1  5  0  5  0     1280  1 
549101d  Muneer ahmed  0  52  62  1.58  0  0  1  1  660  1  0  0  185  140  45  109  1  5  0     1  2  80  0 
339805c  Mohan  0  40  83  1.7  1  1  1  3  470  0  0  1  253  141  34  179  1  5  0  5  0     640  0 
561521d  Anwara Begum  1  48  58  1.54  0  1  0  1  540  1  0  0  318  1138  53  119  1  5  0  5        1280  0 
734160c  Geeta  1  45  93  1.61  1  1  1  3  120  1  0  0  142  136  31  77  0  5  0  5  0     320  0 
864517d  Anand sedan  0  63  68  1.68  1  0  0  1  660  1  0  1  199  101  41  141  0  5  0  5  0     40  0 
544139d  Murali  0  37  68  1.71  0  1  0  1  300  0  0  1  167  163  25  94  0  5  0  5  0     5120  0 
554280d  Chitti babu  0  48  69  1.69  1  0  0  1  300  0  0  0  75  99  24  41  1  5  0  5  0     2560  0 
580631d  Saravanan  0  39  66  1.69  1  1  1  3  110  0  0  1  227  216  44  136  1  5  0  5  0     40  1 
572079d  Prabhu  0  47  73  1.68  1  0  1  2  170  0  1  0  223  219  27  145  1  5  0     1  1  1280  1 
572028d  Md Ali  0  50  90  1.63  0  0  0  0  600  1  1  1  188  156  27  126  1  5  0  5  1  3  2560  0 
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591215d  Vilvanathan  0  62  68  1.69  0  0  0  0  530  0  0  0  106  56  63  37  1  5  1     1  3  320  0 
597371d  Thambi Durai  0  58  71  1.62  1  1  1  3  90  0  1  1  174  63  27  114  1  5  1  5  0     1280  1 
603228d  Neethi Kumar  0  26  96  1.7  1  0  0  1  180  0  0  1  158  192  34  103  1  5  0  5  0     1280  0 
449298d  Sadagopan K V   0  70  69  1.62  1  1  0  2  120  1  1  0  149  210  32  75  1  5  0  5  0     640  1 
563569d  Prabhakaran  0  40  58  1.61  0  1  0  1  600  1  0  1  183  165  34  111  1  5  0  5  0     0  0 
023854d  Natarajan  0  56  66  1.7  0  0  0  0  300  0  0  1  116  80  28  69  0  5  0  5  0     2560  0 
572170d  Sekar G  0  48  51  1.55  0  1  1  2  720  1  1  0  256  121  53  121  1  5  0  5  0     80  0 
603264d  Kumar  0  38  57  1.56  1  1  1  3  180  0  0  1  219  157  37  127  0  5  0  5  0     1280  1 
895316c  Samuel J  0  50  52  1.56  0  1  0  1  480  1  1  0  135  187  41  69  1  5  0     1  3  1280  0 
518292d  Anandan Y  0  45  83  1.68  0  1  0  1  240  0  0  0  221  67  41  148  1  5  0  5  0     1280  1 
609266d  Thangavel  0  66  60  1.62  0  1  0  1  270  1  0  1  148  68  45  78  0  5  0  5  0     640  0 
608492d  Shivalingam  0  62  64  1.64  0  1  1  2  330  0  0  1  236  461  39  127  1  5  0  5  0     640  0 
608541d  Kannaiyan  0  50  76  1.71  1  1  1  3  270  0  0  1  176  140  31  107  1  5  0  5  0     5120  0 
557184d  Abdul Kudhoos  0  35  77  1.6  0  1  0  1  660  0  1  0  169  233  28  95  1  5  0  5  0     1280  0 
591369d  Ilayarasan  0  34  76  1.68  1  1  1  3  60  0  0  0  148  309  24  66  2  1  0  1        0  1 
577374d  Sampath  0  62  64  1.65  0  1  0  1  410  0  1  0  178  227  32  101  0  5  1  5  0     320  0 
559234d  Namasivayam  0  43  63  1.6  1  0  0  1  360  1  0  1  161  102  25  100  0  5  0  5  0     1280  0 
563554d  Rajamani  0  60  64  1.66  0  0  0  0  660  1  0  0  179  97  30  134  1  5  0  5  0     1280  0 
562648d  Malay Acharya  0  49  51  161  1  1  0  2  120  1  1  0  251  350  44  140  0  5  0     1  1  320  0 
570730d  Raman M   0  43  65  1.64  0  0  1  1  660  0  1  0  163  246  32  87  0  5  0     1  2  640  0 
567175d  Samuel Victor  0  62  71  1.62  0  0  0  0  720  0  0  0  236  127  39  148  1  5  0  5  0     1280  0 
607544d  Rafeeq Khan  0  50  70  1.68  1  1  0  2  240  1  1  1  148  122  32  100  0  5  0  5  0     320  1 
549231d  Mohan Raj  0  38  78  1.7  1  1  1  3  60  0  0  1  187  173  35  114  1  5  0  5  0     320  1 
514263d  Bairavan  0  46  65  1.58  0  1  0  1  465  0  0  1  230  56  40  151  0  5  0     1  2  2560  0 
508359d  Joseph S  0  67  62  1.66  0  1  1  2  480  0  0  0  122  140  24  64  1  5  1  5  0     0  0 
608552d  Thirunavukarasu  0  50  76  1.61  0  1  0  1  480  1  0  0  143  131  34  76  0  5  0  5  0     5120  0 
588256d  Kumar L  0  55  65  1.6  1  1  0  2  270  0  0  1  158  147  41  82  1  5  1     1  0  640  0 
582461d  Natesan  0  65  66  1.58  0  0  0  0  660  1  0  0  204  104  38  122  1  5  0  5  0     1280  0 
582136d  Jeeva Amma (F)  1  51  60  1.55  1  1  1  3  210  0  0  0  274  201  41  172  0  5  0  5  0     160  1 
424592d  Govindasamy  0  46  78  1.7  0  1  0  1  180  1  1  1  289  267  43  179  0  5  0     1  1  1280  1 
475812c  Lakshmi (F)  1  56  52  1.48  1  1  0  2  240  1  1  0  274  770  25  137  0  5  0  5  0     320  0 
591543d  Sai K  0  55  61  1.58  0  1  0  1  660  0  0  1  184  148  36  104  0  5  1  5  0     640  0 
106 
 
 
398746d  Dakshinamoorthy  0  61  68  1.68  1  1  0  2  180  0  1  0  133  190  32  69  1  5  0  5  0     10240  1 
439158d  Ragunathan  0  42  60  1.6  1  1  1  3  300  0  0  1  195  124  28  133  1  5  0  5  0     160  0 
432070d  Selvarajan  0  52  54  1.6  1  0  0  1  450  1  0  0  175  112  29  123  0  5  0     1  2  160  0 
500508d  Soundarajan  0  45  66  1.68  1  1  1  3  240  1  1  1  233  697  29  94  1  5  2  5  0     160  0 
505557d  Thanigaimalai  0  59  65  1.58  0  0  0  0  660  1  0  1  217  291  35  121  2  5  0     1  2  1280  0 
572464d  Moorthy  0  45  47  1.55  1  1  0  2  240  0  0  1  109  59  30  59  0  0  0  0  0     0  0 
577958d  Ramamoorthy  0  62  58  1.63  1  1  1  3  180  1  1  1  151  101  26  95  0  5  0  5  0     80  1 
616197d  Vanaja  1  32  73  1.57  1  1  1  3  255  0  0  0  112  94  62  112  1  5  0  5  0     640  0 
537687d  Debabrata  0  52  68  1.62  1  1  0  2  540  1  1  1  178  150  30  107  0  5  0     1  3  80  0 
614050d  Srinivasan  0  36  72  1.68  1  1  0  2  210  0  0  1  185  258  45  100  1  5  0  5  0     320  1 
075027c  Paramasivam  0  68  63  1.6  0  0  0  0  480  0  1  0              1  5  0     1  2  0  0 
422167d  Deiva sigamani  0  70  68  1.58  1  1  1  3  270  1  0  1  130  158  21  75  0  5  2  5  0     0  0 
432188d  Jebasingh  0  48  79  1.63  1  1  1  3  180  1  1  0  217  106  31  155  0  5  0  5  0     0  1 
591218d  Subramani  0  68  51  1.56  1  1  1  3  410  0  0  0  191  474  28  74  1  5  1  5  0     80  0 
745900b  Kannammal  1  65  78  1.56  1  1  1  3  300  1  1  0  128  86  31  71  1  5  0  5  0     160  0 
535088d  Nagarajan  0  67  74  1.62  0  0  0  0  300  1  1  1  144  149  24  83  0  5  0  5  0     1280  0 
449389b  Rajamanickam  0  47  68  1.64  0  0  0  0  300  0  1  0  159  79  37  105  1  5  0     1  2  640  0 
630260d  Nithyanandam  0  53  72  1.75  1  1  1  3  420  0  0  1  208  129  41  137  1  5  0  5  0     80  0 
630425d  Srinivasan  0  56  66  1.65  1  1  1  3  270  1  0  1  179  164  20  118  1  5  0  5  0     80  0 
638125d  Gopal  0  69  58  1.63  1  1  1  3  330  0  0  1  256  126  37  179  1  5  0  5  0     640  0 
630499d  Dasthagir  0  42  74  1.7  1  0  0  1  360  1  0  0  109  192  30  51  1  5  0     1  2  2560  0 
Response to thrombolysis in patients presenting with window period ≤6 hours (Table 23) 
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Response to thrombolysis in patients presenting with window period >6 hours (Table 24) 
 
0
2
4
6
8
10
12
14
16
18
20
N
o.
 o
f p
at
ie
nt
s
Non-responders Probable responders Responders
≤320 320+
 
      Benefit of thrombolysis in patients with window period less than 6 hours (Table 25) 
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Benefit of thrombolysis in patients with window period more than 6 hours (Table 26) 
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MACE in patients in relation to the antistreptokinase antibody titres (Table 33) 
 
0
10
20
30
40
50
60
70
80
N
o.
 o
f p
at
ie
nt
s
≤320 320+
Absent Present
 
